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Abstract 
Individuals with inflammatory bowel disease (IBD) often present with poor bone health 
and have increased risk of osteoporotic bone fractures. The development of targeted 
therapies for this bone loss requires a better understanding of the underlying cellular 
mechanisms. Azathioprine is a commonly used drug for IBD management and has been 
shown to induce autophagy within the colon. However, its mechanisms of action, in 
particular its effects on the skeleton, are not yet fully understood. Herein, the dextran 
sulphate sodium (DSS) model of colitis was induced in mice to examine the effects of 
azathioprine treatment on bone health. Micro-computed tomography assessment of 
vehicle-treated DSS mice revealed a worsened trabecular bone architecture compared to 
vehicle-treated control mice. The azathioprine treated mice were found to have decreased 
bone architecture when treated with the drug alone without the presence of colitis, and 
there was a partial protection provided to the DSS-treated animals with azathioprine 
treatment However, when combined with DSS, azathioprine provides partial protection 
against damage to bone architecture. Histological analysis revealed that azathioprine 
treatment induced autophagy in the bone. This indicates that azathioprine reduces bone 
health in an in vivo a model of IBD. This therefore suggests that azathioprine treatment 
may have a deleterious effect on IBD patients who may already be at increased risk of 
osteoporotic bone fractures and thus will inform on future treatment strategies for patient 
stratification. 
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1.1. Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is the umbrella name given to two similar conditions 
that affect the gastrointestinal system: Ulcerative Colitis (UC) and Crohn’s disease (CD). 
Both diseases are characterised by the inflammation of the gastrointestinal system 
(Pithadia & Jain, 2011).CD can affect any part of the gastrointestinal tract and can cause 
transmural inflammation. In contrast, UC causes mucosal inflammation and is limited to 
the colon (Zhang & Li, 2014). A recent review by NHS England revealed that the 
prevalence of IBD was 1 in every 250 people which results in a total cost of £720 million 
a year in costs to the NHS (NHS England, 2014). 
IBD patients suffer from periods of relapse and remission. During relapse, patients often 
suffer from symptoms such as nausea, fever, abdominal pain, fatigue and weight loss  
(Henderson et al., 2012). Fatigue continues to play a large role in patients day to day life 
even when in remission (Czuber-Dochan et al., 2013). In addition to day to day 
symptoms, IBD can also result in secondary conditions such as colon cancer, arthritis and 
osteoporotic bone loss (Diefenbach & Breuer, 2006). It is this secondary osteoporotic 
bone loss in IBD which is the focus of this thesis. 
In CD, the most affected area of the gastrointestinal tract is the terminal ileum. In more 
than 90% of patients, the disease is located in three main sites: large bowel, isolated small 
bowel disease and the combined involvement of the large and small bowel (Langholz, 
2010). CD results in a granulomatous inflammatory response, a specific form of chronic 
inflammation which is characterised by the collection of epithelioid cells, multinucleated 
cells and macrophages. The development of this inflammatory response depends on a 
complex immune reaction leading to necrosis and fibrosis (Freeman, 2014). CD can be 
diagnosed at any age, but onset is most frequently in the second decade of life. Any early 
onset of CD is often very extensive and is characterised by rapid disease progression 
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(Marcuzzi. et al., 2013). Patients with CD often suffer from strictures of the bowel or 
fistula formation - ulceration that extends through the intestinal wall allowing connections 
between different body parts. Fistula formation can extend into the bladder, the vagina, 
the skin (often following surgery) and most commonly around the anal area (Crohn’s and 
Colitis UK, 2013). 
The inflammation in UC typically involves only the innermost lining or mucosa, causing 
continuous areas of ulceration with no sections of normal tissue (Head. & Jurenka., 2003). 
There a number of varieties of UC: disease involving only the distal area of the colon is 
known as ulcerative proctitis, UC from the descending colon and lower is termed distal 
colitis and any disease involving the whole colon is referred to as pancolitis (Kucharzik 
et al., 2006). Like CD, UC can be diagnosed at any age but usually occurs before the age 
of 30. Because early symptoms are similar to those of irritable bowel syndrome, initial 
diagnosis can be challenging (Head. & Jurenka., 2003).   
1.1.1. Pathogenesis of IBD 
While the pathogenesis of IBD is not entirely understood, it is thought that the genetic 
susceptibility of an individual, the intestinal microbial flora, external environment and 
immune responses are all involved in the development and progression of IBD (Knights 
et al., 2013).  
Several environmental factors play an important role in the pathogenesis of IBD. Factors 
including smoking, diet, gut bacteria, and drugs are all considered to increase IBD risk 
(Diefenbach & Breuer, 2006). Smoking increases the risk of relapse frequency in CD in 
addition to increasing the need for surgery. Contrary to the effect of smoking on CD, 
studies have confirmed that it can have a protective effect on the development of UC 
(Danese et al., 2004). A number of links have also been made between different dietary 
factors and IBD development. It has been observed that a diet high in red meat, margarine 
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and cheese, along with the decreased consumption of fruit and fibre appear to increase 
the risk of IBD development (Maconi et al., 2010). Drugs such as antibiotics and 
nonsteroidal anti-inflammatory drugs (NSAIDs) are two of the main classes of drugs that 
effect the development of IBD. NSAIDs have been associated with increased risk of CD 
and UC when used for a prolonged time (Zhang & Li, 2014). Antibiotics have also been 
found to increase the risk of IBD as a result of their effect on the microbiome. This is 
especially common in children diagnosed with IBD as it has been found that infants with 
IBD were often found to have used antibiotics in their first year of life (Shaw et al., 2010). 
The intestinal immune system is responsible for defending against pathogens and the 
entry of intestinal microbes. An imbalance in this process is considered to predispose to 
IBD (Abraham & Medzhitov, 2011). Patients with IBD have altered immune mechanisms 
of the epithelial layer. It is thought that IBD occurs when a breakdown in the epithelial 
barrier exposes immune cells to bacteria and luminal antigens (Shih et al., 2008). The 
breakdown of the epithelial layer combined with a genetic predisposition is thought to be 
required to trigger IBD. An upregulation of NOD2 in epithelial cells may also cause a 
reduction in the hosts ability to eliminate pathogenic microbes and this can result in 
chronic inflammation (Baumgart & Carding, 2007).  
Over the last few decades, advances in genetic testing has allowed for the completion of 
many genome-wide association studies (GWAS) which has allowed the identification of 
single nucleotide polymorphisms (SNPs) associated with IBD. GWAS have identified 
more than 200 IBD associated susceptible loci (Nishida et al., 2017). Some of these 
susceptibility genes are known to be involved in mediating the responses of the host to 
gut microbiota (Nishida et al., 2017).  Over 28 genes have been linked with both forms 
of IBD whereas some loci have been found to be specific to CD or UC which may provide 
a new way to look at the common pathogenesis of UC and CD (Zhang & Li, 2014). Some 
of the CD-related genes found include Nucleotide-binding oligomerization domain-
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containing protein 2 (NOD2), autophagy-related 16 (ATG16) and immunity-related 
GTPase family M (IRGM), as is discussed further in section 1.5 (Kohr et al., 2011).  
The association between NOD2 and IBD was made in 2001 and it was found that 
homozygous mutation of NOD2 gene increases the risk of developing IBD 20 to 40 fold 
(Hooper et al., 2017). NOD2 is highly expressed in macrophages, dendritic cells and in 
epithelial cells of the intestine. It is activated by N-acetyl muramyl dipeptide and binds 
to receptor interacting serine-threonine kinase 2 (RIP2, RIPK2) which results in the 
activation of the NF-kB pathway (Kaser et al., 2010). The variant of NOD2 associated 
with IBD does not bind to RIP2 which decreases the activation of the NF-kB pathway.  
ATG16L1 is located on chromosome 2 at 2q37.1 and encodes a protein that is involved 
in autophagosome formation. ATG16L1 was first identified in 2007 as a susceptible gene 
for IBD (Hampe et al., 2007). A SNP shown by the marker rs2241880, that encodes a 
threonine to alanine substitution (T300A) was linked to CD susceptibility (Hampe et al., 
2007). A mouse model with ATG16L1 deficiency showed Paneth cell dysfunction along 
with increased expression of pro-inflammatory cytokines and lipid metabolism genes, 
similar to the Paneth cell phenotype of CD patients (Marcuzzi. et al., 2013). Paneth cells 
are secretory epithelial cells of the small intestine that are key effectors of the innate 
mucosal defence (McSorley & Bevins, 2013). 
The IRGM gene is found on chromosome 5q33.1 and was reported as being an IBD 
susceptible gene in 2007 (Parkes et al., 2007). In humans, IRGM is formed from 181 
amino acids and is found in the small and large intestine and expressed by lymphocytes. 
IRGM is known to be involved in virus-induced autophagy, phagosome maturation and 
bacterial killing (Jo, 2013). IRGM encodes a GTP-binding protein that is involved in the 
regulation of autophagy activating in response to intracellular pathogens (Rufini et al., 
2015). It has been found that IRGM regulates a complex that includes NOD2 and 
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ATG16L1 which is necessary for the activation of autophagy. These genes are involved 
in bacteria-immune interactions and indicate impaired autophagy of invasive gut 
microbes (Kohr et al., 2011).  
1.2. Autophagy 
Autophagy protects cells from several pathological stresses and also plays a crucial role 
during development and in the maintenance of cellular homeostasis (Iriarte Rodríguez et 
al., 2015). There are three different autophagic routes: macroautophagy, microautophagy 
and chaperone-mediated autophagy (CMA) (Choi et al., 2013).  Microautophagy is the 
non-selective lysosomal degradative process which involves the direct engulfment of 
cytoplasmic material at a boundary membrane by autophagic tubes which are responsible 
for the mediation of vesicles scission into the lumen (Jian & Bao, 2012). CMA is a 
selective form of autophagy through which specific cytosolic proteins are transported 
individually across the lysosomal membrane for degradation (Orenstein & Cuervo, 2010). 
The most common form of autophagy is microautophagy, herein referred to as autophagy, 
and this is an essential self-eating process that allows the degradation of intracellular 
components such as organelles, foreign bodies and soluble proteins (Yu et al., 2017).  
One of the main features of the autophagy pathway (Fig. 1.1) is the formation of 
endomembranous organelles called autophagosomes. A number of factors such  Beclin 1 
and autophagy related (ATG) proteins are key regulators driving the formation of the 
autophagic isolation membrane, also referred to as the phagophore (Deretic et al., 2013). 
The phagophore is derived from phosphatidylinositol 3-phosphate (PI3P)-positive 
domains of the endoplasmic reticulum known as omegasomes. The Golgi, mitochondria 
and other membrane derived organelles also contribute to the formation of the 
phagophore (Klionsky & Codogno, 2013). The essential genes required for the formation 
of the autophagosome  are referred to as the core machinery genes (Kang et al., 2018). 
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They are classed into three groups: transmembrane proteins (example ATG9), the 
phosphoinositide-3-kinase (PI3K) complex and ubiquitin-like protein conjugation 
systems (ATG12 and ATG8/LC3).  
Next, a complex is formed on the phagophore between ATG16L1 and ATG5-12 which 
then lapidates LC3, the mammalian homologue of Atg8 found on both the outer and inner 
membranes of the autophagosome. At the same time, the phagophore elongates to engulf 
the cytoplasm or organelle destined to be degraded thus forming an autophagosome, a 
unique double-membrane organelle (Iida et al., 2017). There are two forms of LC3- LC3I 
and LC3II. LC3 is cleaved by Atg4 to liberate a C-terminal glycine needed for the 
conjunction to phospholipids upon the induction of autophagy. This binding forms LC3II 
and is essential for the extension and closure of the phagophore to form the 
autophagosomes (Iii et al., 2010; Glick et al., 2010). LC3II is present throughout the 
membrane to help select the material to be engulfed by the autophagosome and assists 
with the membrane fusion (Glick et al., 2010; Itakura & Mizushima, 2011). LC3 is a 
dependable way to monitor autophagy activity as the amount of LC3-II, the conjugated 
form of LC3 correlates with the number of autophagosomes (Kuma et al., 2007). 
Bafilomycin can be used to inhibit autophagy through the inhibition of the acidification 
of the lysosome that stops the cargo from being degraded (Vinod et al., 2014). 
Bafilomycin was also found to block the fusion of the autophagosome to the lysosome 
(Yamamoto et al., 1998). Because of this bafilomycin can be used to measure autophagy 
levels as it results in the build-up of autophagy marker LC3-II (Figure 1.1). 
The intracellular protein degradation mechanism is then triggered when the 
autophagosome matures and fuses with lysosomes to degrade its contents. The first step 
of autophagosome fusion is when the outer membrane fuses with a single lysosome 
membrane. The fusion is complete when the inner autophagosomal membrane is 
degraded by lysosomal hydrolases and the contents are exposed to the lumen of the 
Chapter 1: Introduction 
8 
 
lysosome (Yu et al., 2017). The amino acids and other products of degradation are 
exported back into the cytoplasm by lysosomal permeases and transporters. Here they can 
be used for building macromolecules and for metabolism (Glick et al., 2010). 
 
 
 
 
 
 
 
 
Figure 1.1. Autophagy pathway showing the formation of the autophagosome and 
resulting degradation of cargo whilst indicating the proteins and autophagy markers 
involved at the different stages of formation. 
 
1.2.1. Autophagy signalling pathways 
Autophagy is triggered by a number of inductive signals that begin the formation of the 
phagophore (Hurley & Schulman, 2014). Two of the systems that control the autophagy 
process are the mTOR-ULK1 and the beclin-1 pathway (Lilienbaum, 2013). 
mTOR or mechanistic target of rapamycin, phosphorylates and inactivates Atg13 and 
ULKs under nutrient rich conditions. The inhibition of mTOR can be caused by starvation 
or treatment with rapamycin, resulting in the activation of  ULK1, ULK2 and 
phosphorylate Atg13 which is essential for autophagy (He & Klionsky, 2009). There are 
two forms of mTOR, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). 
Bafilomycin A1 
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mTORC1 is involved in anabolic processes such as translation, lipid synthesis and tRNA 
production. It is also involved in the regulation of energy through the repression of 
autophagy when conditions are nutrient sufficient (Mckee-muir & Russell, 2017). 
However, mTORC2 is not sensitive to nutrient sufficiency and is responsible for the 
downstream regulation of pathways including PI3K-AKT and cytoskeletal organisation 
(Gaubitz et al., 2016). P62 is a scaffold protein that helps to regulate ubiquitin-mediated 
downstream signalling from multiple receptors including toll-like receptors and TNF 
receptors (Ciuffa et al., 2015). P62 been found to be a regulator of mTORC1 activation 
to regulate the nutrient sensing response (Duran et al., 2016). During autophagy, p62 is 
constantly degraded due to its binding with LC3 which keeps the expression of p62 low 
in non-stressed cells. P62 is upregulated when autophagy is disrupted which makes it a 
good marker for autophagy activity (Duran et al., 2016). 
The autophagosome nucleation during autophagy requires a complex which contains 
Atg6 or its mammalian homolog Beclin1. Beclin1 recruits phosphatidylinositol (PI) 3-
kinase which is used to generate PI3P (Qian et al., 2017). PI3P recruits proteins to 
modulate intracellular trafficking and the formation of the autophagosome (Kim et al., 
2012). The process started with the beclin1 results in the development of the 
autophagosome membranes. 
1.3. Current treatments of IBD 
Despite substantial research and further development in IBD treatment, patients are not 
often able to return to their former quality of life. There are a number of different 
treatment options including thiopurines and corticosteroid. However, apart from the 
mildest of cases, a lot of treatment is through immunosuppression, often leading to 
surgery (Diefenbach & Breuer, 2006). IBD drugs are often used in combination to limit 
side effects and make the treatment more effective for the patient. 
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1.3.1 Aminosalicylates  
Aminosalicylates such as sulphasalazine and mesalazins are anti-inflammatory treatments 
that are used to induce and maintain remission in patients with UC however clinical trials 
have not shown them to be as effective in the treatment of CD (Hanauer, 2004). Many 
mechanisms of action have been described including the scavenging of damaging reactive 
oxygen species (ROS), inhibition of leukocyte motility, interference with nuclear factor-
kappa B (NFκB) and the inhibition of IL-1 synthesis (Desreumaux & Ghosh, 2006). It 
was recognised that 5-aminosalicylic acid (5-ASA) is the active moiety in UC has allowed 
the development of numerous medication formulas including sulfasalazine (sulfapyridine 
bound to 5-ASA) (Hanauer, 2004).  
1.3.2. Corticosteroids 
One of the first methods of treatment to induce remission for IBD is through the use of 
corticosteroids which downregulate proinflammatory cytokines (Iida et al., 2017). 
Although the use of corticosteroids has been seen to reduce remission in 84% of patients, 
long term treatment is often not an option due to severe adverse effects and the steroid 
dependency seen in 30-45% of patients (Markowitz, 2008). Long term effects include 
bone loss, venous thromboembolism and poor wound healing (Waljee et al., 2016). The 
use of corticosteroids in IBD reduce inflammatory mediators by binding with the 
glucocorticoid receptor expressed by immune cells. The binding results in the expression 
of proinflammatory transcription factors such as NFκB and the apoptosis of target 
inflammatory cells (Lichtenstein, 2006).  
1.3.3. Immunomodulators 
Methotrexate, cyclosporin and tacrolimus are forms of immunomodulatory drugs that are 
mainly used to maintain remission is severe forms of IBD (Pithadia & Jain, 2011). 
Methotrexate works by inhibiting RNA and DNA synthesis in dividing cells whereas 
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cyclosporin and tacrolimus block the production of IL-2 that results in a reduction of T 
cell activity (Dieren et al., 2006; Markowitz, 2008). Treatment with immunomodulators 
can have several side effects including nausea, bone marrow suppression and ulcerative 
stomatitis (Markowitz, 2008). Concentration of thiopurine metabolites are closely 
monitored in patients as high levels can result in hepatotoxicity and myelosuppression 
(Hooper et al., 2017).  
1.3.4. Biologic agents 
Biologic agents such as infliximab are anti-inflammatory drugs that work by binding to 
both soluble and membrane bound TNF in both CD and UC (Markowitz, 2008). Therapy 
with infliximab is used for both the induction and maintenance of remission due to the 
removal of TNF from the circulation and death of lymphocytes and monocytes which are 
essential to the initiation of inflammation (Hyams et al., 2007; Moss & Farrell, 2006). In 
addition, infliximab is used to reduce the number of rectovaginal fistulas and maintaining 
fistula closure in patients with fistulising CD (Lichtenstein, 2006). 
1.3.5 Thiopurines  
Thiopurines have been proven effective in IBD in maintaining remission, monitoring 
steroid withdrawal and fistula closure (Dubinsky, 2004). Examples of thiopurines are 
Azathioprine and Mercaptopurine which are taken by as many as 60% of patients (Cosnes 
et al., 2005). Both drugs have a slow onset of action but are able to maintain remission in 
moderate to severe cases of IBD (Gisbert et al., 2011). Although the use of 
mercaptopurine has a steroid sparing effect during remission the side effects of the drugs 
may outweigh the benefits of thiopurines. Side effects of thiopurine use can be severe 
with patients suffering from nausea, pancreatitis and recurrent infections. There is also a 
risk of developing lymphoma as a result of treatment (Dubinsky, 2004).   
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Azathioprine is converted to 6-mercaptopurine (6-MP) in the intestinal wall, liver and red 
blood cells via glutathione. The drug is broken down into thiopurine metabolites, 
methylmercaptopurine nucleotides and thioguanine nucleotides. The nucleotides cause 
the inhibition of DNA, RNA and protein synthesis resulting in immunosuppression 
(Stocco et al., 2015). It was observed that autophagy may play a protective role against 
the adverse effects caused by thiopurine treatment as autophagy was seen to be induced 
in hepatocytes upon treatment with azathioprine (Hooper et al., 2017). The mechanism of 
action of azathioprine is known to involve both apoptosis and autophagy and azathioprine 
has previously been found to induce autophagy in peripheral blood mononuclear cells and 
colorectal cancer cells (Hooper et al., 2019; Chaabane & Appell, 2016). 
 
1.4. Bone 
The skeleton is a highly intricate and complex organ that is adapted to suit its function, 
being both strong yet light allowing it to withstand loading whilst allowing movement 
and flexibility to prevent fractures (Farquharson & Staines, 2011). The human adult 
skeleton is made up of 206 separate bones which are supported by cartilage, muscles and 
tendons. The skeleton contains 99% of the total calcium in the human body and is 
specialised for the protection of vital organs, mineral homeostasis  and the regulation of 
metabolism (Brandi, 2009). Bone is made up of both organic and inorganic material and 
a combination of organic collagen and hydroxyapatite mineral results in a structure that 
is strong and resistant to fracture (Staines et al., 2012).  
Bone forms by two distinct mechanisms, both of which involve a number of different 
biochemical and morphological processes. The development and formation of flat bones, 
such as the skull and clavicle, happens as result of a process called intramembranous 
ossification which involves the direct differentiation of embryonic mesenchymal cells 
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into osteoblasts (see section 1.2.2.1) (Mackie et al., 2011). In contrast long bones such as 
the femur are formed by endochondral ossification which involves a cartilage anlagen 
being replaced by bone tissue (Mackie et al., 2011). Long bones consist of the epiphyses 
and metaphyses at each end, and the diaphysis in the middle. Located in the metaphysis 
is a developmental cartilaginous region termed the growth plate. The growth plate is 
responsible for postnatal bone growth and consists of chondrocytes arranged in columns 
surrounded by their extracellular matrix (ECM). The chondrocytes of the growth plate sit 
in distinct cellular zones of maturation and undergo defined stages of differentiation to 
enable longitudinal bone growth (Mackie et al., 2011). This continues until sexual 
maturity has been reached at which point the growth plate fuses through the formation of 
bone bridges and it replaced by a epiphyseal line (Shapiro, 2008). 
The skeleton consists of two different types of bone tissue, cortical bone and trabecular 
bone. The cortical bone makes up around 80% of the skeleton and is found in the shafts 
of long bones and the outer surfaces of flat bones (Brandi, 2009). Cortical bone is well 
organised into osteon building units which have resident osteocytes (see section 1.2.2.3). 
These osteocytes run through a canaliculi network which connects the osteocytes with 
osteoblasts and osteoclasts on the bone surface (Sommerfeldt & Rubin, 2001). The 
trabecular bone is found mainly at the end of long bones and in the inner parts of flat 
bones (Brandi, 2009). The trabecular bone consists of an open lattice network with 
abundant haemopoietic tissue and fat, thereby reducing the weight of bone. Compared to 
the cortical bone, trabecular bone has a high turnover rate and can adapt to loading in 
multiple directions (Sommerfeldt & Rubin, 2001). The proportions of the two different 
types of bone tissue vary depending on the skeletal site (Brandi, 2009) (Fig. 1.2). 
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1.4.1. Bone mineralisation 
Bone mineralisation begins with membrane bound matrix vesicles (MV) which are 
formed by both osteoblasts and chondrocytes. These vesicles provide a protective 
environment for calcium ions (Ca2+) and inorganic phosphate (Pi) to accumulate (Staines 
et al., 2014). High concentrations of Ca2+ and Pi leads to their precipitation into 
hydroxyapapite crystals. These crystals then increase in size and pass through the MV 
membrane where they are deposited onto collagen fibrils (Anderson, 2003). This process 
is regulated by several factors such as alkaline phosphatase and non-collagenous proteins 
(NCPs) (Olszta et al., 2007). 
 
Figure 1.2. Cross section of human femur showing the trabecular and cortical bone. 
Taken from (Hambli & Hattab, 2013). 
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1.4.2. Bone modelling and remodelling 
Bone modelling happens as a result of bone formation and resorption and causes changes 
to the size and shape to allow the bone to adapt to any changes in mechanical loading. On 
the other hand, bone remodelling replaces old bone with new bone without any changes 
in the overall bone mass (Raggatt & Partridge, 2010). Bone is constantly remodelled 
throughout the entire lifetime which allows the complete skeleton to be replaced every 10 
years (Weinstein & Manolagas, 2000). There are three types of cells involved in the bone 
remodelling process; osteoblasts which are responsible for bone formation, osteoclasts 
which are involved in bone resorption and osteocytes which are responsible for forming 
a network between other cells in the bone and as such, play a key role in the regulation of 
bone remodelling (Manolagas, 2000). 
1.4.2.1. Osteoblasts 
Osteoblasts are specialised bone forming cells which are differentiated from 
mesenchymal stromal cells (MSC)s (Jung et al., 2008). Osteoblasts account for 4-6% of 
the total bone cells and are responsible for the secretion of the osteoid which mineralises 
to offer strength to the skeleton (Florencio-Silva et al., 2015). Osteoblasts are 
characterised by prominent Golgi apparatus, rough endoplasmic reticulum as well as a 
number of secretory vesicles (Florencio-Silva et al., 2015).  
The differentiation of osteoblasts involves several factors including transforming growth 
factor-beta (TGF-β), bone morphogenic protein (BMP) and transcription factors such as 
Runx2, osterix and β-catenin (Chen et al., 2012: Komori, 2006). Once the process is 
activated by expression of Runx2, the MSCs undergo a three-stage differentiation. Firstly, 
the cells continue to proliferate and express collagen type I, osteopontin and TGF- β. They 
then begin to differentiate while maturating the ECM with collagen type I and alkaline 
phosphatase. Then matrix mineralisation then occurs due to the abundance of osteocalcin 
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which promotes the deposition of mineral substance. At this stage the osteoblast forms its 
characteristic cuboidal shape (Rutkovskiy et al., 2016).  
There are many known markers of the osteoblast phenotype including osteocalcin 
(Bglap), periostin (Postn) and collagen type 1 (Col1a1) (Florencio-Silva et al., 2015: 
Garnero, 2009). Osteocalcin is a non-collagenous, vitamin K-dependant protein that is 
produced by osteoblasts (Razzaque, 2011). It is coded for by the Bglap gene in mice and 
provides a non-invasive marker of osteoblast activity and bone formation. The osteocalcin 
protein contains three residues of the amino acid gamma-carbo-xyglutamic acid (Gla). In 
the company of calcium, the Gla residues facilitate the binding of osteocalcin to HA and 
deposition in the bone matrix (Razzaque, 2011). Periostin is an extracellular matrix 
protein which is coded for by the Postn gene and is expressed in osteoblasts (Cobo et al., 
2016). Periostin null mice have been found to have undersized bones, a restricted 
trabecular network and often suffer from dwarfism (Rios et al., 2005). Loss of 
malfunction has been found to result in altered trabecular and cortical bone 
microarchitecture and overall lower bone density (Chapurlat & Confavreux, 2016). 
Collagen type 1 is encoded by Col1a1 in mice, is secreted by osteoblasts and provides the 
scaffold for the deposition of HA crystals in bone mineralisation (Van Dijk et al., 2010: 
Nudelman et al., 2010). Genetic polymorphisms of Col1a1 is associated with low bone 
mineral density and high fracture risk in humans (Kostik et al., 2013). 
Once the osteoblast has matured and has deposited the bone ECM, it either differentiates 
into an osteocyte by a process known as osteocytogenesis (see section 1.2.2.3) or 
undergoes apoptosis (Dallas & Bonewald, 2010). 
1.4.2.2. Osteoclasts 
Osteoclasts are a part of the monocyte/macrophage lineage and are formed when multiple 
mononuclear cells fuse together in the bone marrow. The receptor activator of nuclear 
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factor kappa-B (RANK) is found on osteoclast precursor cells and contains a tumour 
necrosis factor (TNF) receptor-associated factor (TRAF). The ligand for RANK receptor 
(RANKL) is expressed on the surface of mesenchymal cells, lymphocytes and 
osteoblasts. The binding of RANK to RANKL induces osteoclast differentiation. RANK 
controls the initiation of downstream molecules through the use of TRAF that results in 
osteoclast differentiation (Kim & Kim, 2016). The signals produced from the downstream 
molecules are involved in the stimulation of tartrate-resistant acid phosphatase (TRAP)- 
which is a recognised marker of osteoclast differentiation (Kim & Kim, 2016). 
Osteoclasts are responsible for the resorption of bone a process which is closely regulated 
to prevent the development of different bone disorders (Väänänen & Laitala-Leinonen, 
2008). Osteoclasts adhere to the bone matrix through the formation of a ruffled border, 
and then secrete acid and lytic enzymes that cause degradation. 
1.4.2.3. Osteocytes 
Osteocytes comprise of 90-95% of all bone cells and have a lifespan of up to 25 years 
(Franz-Odendaal et al., 2006). Osteocytes are located within lacunae embedded in 
mineralised bone ECM and have a unique dendritic morphology. Osteocytes are 
surrounded by a canalicular fluid which delivers nutrients and oxygen from the 
circulation. This fluid carries hormones and provides access to therapeutic drugs 
(Compton & Lee, 2014). Osteocytes are derived from the differentiation of osteoblasts 
and this process occurs in four stages, termed osteocytogenesis: osteoid-osteocyte, 
preosteocyte, young osteocyte and mature osteocyte (Franz-Odendaal et al., 2006). One 
of the first things to happen in the embedding cell is the development of dendritic 
processes. These dendrites form towards the mineralising front and then extend further to 
either the bone surface or vascular space enabling the osteocyte to connect with other 
osteocytes, osteoblasts and osteoclasts. The osteocyte is thought to carry out many 
functions concurrently, including mechanotransduction, calcium and phosphate 
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regulation and the regulation of bone remodelling (Bonewald, 2011). A marker that 
osteocytes have become mature is the production of the Wnt inhibitor sclerostin which 
acts as a negative regulator for bone formation (Bonewald, 2011). More recently it has 
been shown that osteocytes regulate bone remodelling through the expression of RANKL 
(Xiong et al., 2012: Nakashima et al., 2011).  
1.4.2.4. Osteoporosis 
Osteoporosis is a skeletal disorder that is characterised by low bone mass (Figure 1.3) 
with an increase in bone fragility thus making individuals with osteoporosis susceptible 
to fracture (Sambrook & Cooper, 2010). This is due to an imbalance in the bone 
remodelling process, in favour of increased bone resorption. Osteoporosis has been 
associated as secondary to  a number of gastrointestinal conditions including IBD and it 
is estimated that more than 35% of patients with IBD will develop osteoporosis (Ali et 
al., 2010: Bianchi, 2010).  
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1.5. Inflammatory bowel disease and bone 
Both forms of IBD, UC and CD, are associated with a significant reduction in bone mass 
in both adults and children. CD often affects bone mass more severely than UC especially 
in growing children, most likely because CD affects linear growth and normal 
development of the skeletal muscle mass more so than UC (Sylvester & Vella, 2016). The 
occurrence of osteopenia in IBD is 32-36% and osteoporosis is 7-15%. Indeed patients 
with IBD are 40% more at risk of bone fracture than a healthy individual (Ali et al., 2010: 
Agrawal et al., 2011). 
Figure 1.3: Changes in architecture between normal 
and osteoporotic bone. Images provided from the Bone 
Research Society, by kind permission of Tim Arnett. 
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Bone loss in IBD is thought to be caused by two main factors, malabsorption and 
inflammation (Bianchi, 2010). Intestinal absorption of key determinants of bone health – 
e.g. Ca2+ and vitamin D - is often altered in IBD due to the reduction of intestinal mucosa 
(Bianchi, 2010). In addition, patients with IBD often reduce or avoid milk and other dairy 
foods therefore limiting the calcium available for absorption. The loss of albumin and 
immunoglobulins is well documented in IBD and since vitamin D is carried in the plasma 
by vitamin-D binding globulin the loss of vitamin D is common in IBD patients (Bianchi, 
2010). 
In IBD, the immune response leads to the production of proinflammatory cytokines such 
as interleukin (IL) -2 and tumour necrosis factor (TNF). In mononuclear cells, (NFκB) 
regulates the transcription of IL -1, 6 and 8. It also regulates proinflammatory genes such 
as chemokines and TNF-α (Ali et al., 2010). Many proinflammatory osteoclast activators 
including TNF-α and IL -1,6,11 and 17 are upregulated in patients with IBD, thereby 
providing a potential mechanism in favour of increased osteoclast function. Variations in 
the IL-6 and IL-1 receptor genes have also been connected with the clinical course of IBD 
and the degree of bone loss (Schulte et al., 2000). Chronic inflammation is mediated by 
T-cells which can produce RANKL that can trigger bone loss through the activation of 
osteoclasts (Clowes et al., 2005). 
A model of IBD has been utilised in a number of studies using dextran sulphate sodium 
(DSS) to induce colitis in mice. The DSS treatment induces colitis by causing a toxic 
effect on intestinal cells. This leads to a fissure in the mucosal barrier which exposes the 
contents to luminal antigens which results in inflammation (Hamdani et al., 2008). DSS 
produces similar effects to UC such as mucosal inflammation and focal crypt legions and 
also displays features of CD such as ulceration and submucosal inflammation (Harris et 
al., 2009). The treatment with DSS has been previously linked to a reduction in bone mass 
and formation and therefor makes an effective model to observe bone loss in IBD. 
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1.6. Autophagy and bone 
1.6.1. Autophagy in osteoblasts 
Osteoblasts are derived from MSCs and evidence suggests that autophagy is crucial for 
these MSC progenitors. It has been shown that the induction of autophagy could produce 
a survival response against oxidative stress in MSCs from the bone marrow (Song et al., 
2014). An accumulation of autophagic vacuoles is observed in undifferentiated MSCs, 
and these are consumed during early differentiation into osteoblasts, indicating that they 
are used as a source of energy (Nuschke et al., 2014). Further, the differentiation of MSCs 
is also reported to be controlled by AMPK through early mTOR inhibition-mediated 
autophagy (Pierrefite-Carle et al., 2015).  
Osteoblasts are responsible for bone formation through the secretion of bone ECM and 
the ensuing ECM mineralisation. Intracellular mineralisation could be mediated by 
autophagy through autophagic vacuoles acting as vehicles for HA crystal secretion 
(Pierrefite-Carle et al., 2015). Further, it has been shown that autophagy is involved in 
major aspects of osteoblast ECM mineralisation (Nollet et al., 2014). When autophagy is 
inhibited, osteoblast ECM mineralisation has been found to decrease which could suggest 
that autophagic vacuoles could serve to secrete HA crystals to the extracellular space 
(Nollet et al., 2014). The disruption of NBR1, an autophagic receptor for the degradation 
of ubiquitinated substrates, has an effect on the activity and differentiation of osteoblasts 
(Waters et al., 2009). NBR1 manages this by interacting with LC3 protein members 
through its LC3- interacting region and by binding with the targets through the ubiquitin-
like modifier activating enzyme (UBA) domain (Shapiro et al., 2014). In a mouse model 
where the NBR1 protein is inhibited, high bone mass and increased bone mineral density 
was observed in older mice as a result of the increased osteoblast activity (Whitehouse et 
al., 2010).  
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Certain families of transcription factors are known to have roles in autophagy and assist 
in the control of osteoblast survival and function. One family, FOXO transcription 
factors, plays key roles in cell growth and proliferation, energy homeostasis and glucose 
metabolism (Demontis & Perrimon, 2010). The activation of FOXO induces autophagy 
through the direct binding to the promotor region of the target genes. The genetic deletion 
of FOXO transcription factors in osteoblasts increases apoptosis and oxidative stress 
which mimics the aging process (Almeida, 2011). Because of the role of autophagy in 
protection against oxidative stress it is thought that the induction of autophagy may 
mediate the role of FOXO in the maintenance of bone homeostasis. 
The skeletal adaptive response to mechanical loading is mediated by osteoblasts and 
osteocytes. They do this by causing a cascade of biochemical and structural changes in 
response to mechanical forces. It has been observed that autophagy is sensitive to changes 
in mechanical pressure in mammalian cells (King et al., 2011). Certain pressures, around 
the control of 0.2kPa are required to cause changes in osteoblasts whilst also inducing 
autophagy (Kanzaki et al., 2002). Once again, it can be observed that autophagy plays a 
key role in bone homeostasis.  
1.6.2. Autophagy in osteocytes 
Osteocytes are terminally differentiated osteoblasts and are found embedded within the 
mineralised bone. Due to their long life and location, osteocytes are known to be 
dependent on autophagy for their survival (Zahm et al., 2011). Autophagy is also induced 
in osteocytes in response to hypoxia and starvation, both which often occur in their usual 
environment. In pre-osteocyte-like murine cells (MLO-A5), autophagy was found to be 
upregulated in response to calcium stress and hypoxia inducible factor 1, α subunit 
(HIF1A) which indicates that low oxygen pressure serves as a positive regulator of 
autophagy (Zahm et al., 2011). The induction of autophagy in osteocytes was shown to 
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offer protection in response to cellular stress caused by glucocorticoid treatment and thus 
prolonging the survival of the osteocytes (Xia et al., 2010). An age-related decline in 
autophagic activity has also been described in rat osteocytes with a decrease in LC3 and 
Beclin-1 observed whilst the expression of p62 and levels of apoptosis were increased 
(Chen et al., 2014). 
1.6.3. Autophagy in osteoclasts 
Osteoclasts are multinucleated cells that are formed by the joining of multiple myeloid 
precursors. This is triggered by RANKL and M-CSF,  and monocyte chemotactic protein-
1 (MCP-1) is also known to induce this differentiation process (Kim et al., 2006). It was 
observed MCP-1 differentiation is mediated by Beclin-1 upregulation and autophagy 
(Wang et al., 2011). TRAF3, which is involved in the suppression of RANKL-induced 
osteoclast formation, is degraded by autophagy as a result of RANKL in osteoclast 
precursors from bone marrow (Xiu et al., 2014).  
Further, it has been shown that some of the ATGs such as Atg5, Atg7 and LC3 are 
required for the osteoclast ruffled border generation, bone resorption and secretory 
activity. Atg5 attracts LC3-II to the ruffled border and this induces the fusion of the 
osteoclast plasma membrane with lysosomes which is needed in the resorption of bone 
(DeSelm et al., 2011). Osteoclast activity was further associated with the conversion of 
LC3-I to LC3-II. However, the knockdown of LC3 did not affect TRAP-positive 
multinucleated osteoclasts cell formation, but suppressed the osteoclast bone-resorbing 
capacity (Chung et al., 2012).  
1.6.4. Autophagy in osteoporosis 
As evidenced above, autophagy plays a vital role in the maintenance of bone homeostasis 
and therefore any alterations in this pathway are related to the development of 
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osteoporosis (Florencio-Silva et al., 2017a). Besides the loss of sex hormones, increased 
oxidative stress is recognised as a major factor in the development of osteoporosis which 
suggests that autophagy could play a critical role in age-related bone loss (Almeida & 
Brien, 2013).  
The effect of the mTOR pathway on skeletal growth has recently been explored and it 
was found that rapamycin, an inhibitor of mTOR, can reduce the growth of body weight,  
alter the growth of long bones, cause changes to the structure of the growth plate and 
affect fracture healing (Shen et al., 2018). mTOR signalling inhibitors have been used in 
the treatment of osteosarcoma suggesting that the inhibition of mTOR may also have a 
positive impact on bone (Moriceau et al., 2010). It has been suggested that the interaction 
of mTOR signalling with other pathways such as NF-κB or RANKL may also be a 
potential mechanism of action for osteoporosis and thus could be a promising therapeutic 
target (Shen et al., 2018). 
Further, treatment of male mice with high levels of glucocorticoids reduced the 
percentage of LC3 positive osteoblasts resulting in the a loss of cell viability and 
subsequent osteoporotic bone loss (Yao et al., 2016). However, the administration of an 
antibody against sclerostin, an inhibitor of bone formation, prevented glucocorticoid-
induced bone loss by increasing autophagy and maintaining the health of osteoblasts. 
Together this therefore suggests that increases in autophagy may protect against bone loss 
in osteoporosis. However, the role of autophagy in IBD-related osteoporosis has yet to be 
established.   
1.7. Aims  
The aim of this study is to investigate the effects of the IBD drug azathioprine on bone 
health. It will test the hypothesis that: azathioprine stimulates autophagy in the skeleton 
in IBD and thus provides protection against IBD-related osteoporosis.  
Chapter 1: Introduction 
25 
 
To address this hypothesis, this study will examine the following aims: 
1) Assess the effects of azathioprine on bone health in an in vivo model of IBD. This will 
test the hypothesis that: azathioprine has a detrimental effect on bone health in an in vivo 
model.  
2) Determine whether azathioprine modulates autophagy in the skeleton. By determining 
the stimulation of autophagy by azathioprine, it will test the hypothesis that: azathioprine 
induces autophagy in the skeleton in IBD therefore providing a defence against 
osteoporosis resulting from IBD. 
Results from this study may help to prevent unwanted side effects of azathioprine 
treatment on bone health in IBD patients and both the economic and social burden of this 
disease.
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2.1. Animal study 
An IBD in vivo murine model, previously established by the research team, was used to 
investigate the effects of azathioprine on IBD-related bone health (Dobie et al., 2017). 
Ten-week old male mice (n=6/group) (Charles River, UK) were treated with 3% dextran 
sulphate sodium (DSS) (MP Biomedical, UK) in their drinking water for 4 days to induce 
colitis (Fig. 2.1). Following this they were given a 14-day recovery period where they 
were given normal water. Mice were treated using an oral gavage throughout the 
experiment with 10 mg/kg/day of azathioprine or a vehicle control (n=6/group). Control 
mice (non-DSS treated), receiving either the vehicle control or azathioprine were treated 
with normal tap water for the duration of the study. Overall, there were 4 treatment groups 
utilised in this study, DSS treatment with a vehicle control, DSS treatment with 
azathioprine, water with vehicle control and water with azathioprine. The health of the 
mice was monitored throughout the experiment by taking the weight of each mouse daily 
and closely monitoring the health of their coats and behaviours. Mice were kept in 
polypropylene cages, with light/dark 12-hr cycles, at 21 ± 2°C, and fed ad libitum with 
maintenance diet (Special Diet Services, Witham, UK). All experimental protocols were 
approved by Roslin Institute’s Animal Users Committee and the animals were maintained 
in accordance with UK Home Office guidelines for the care and use of laboratory animals. 
 
 
 
 
 Figure 2.1: Schematic of the in vivo experiment over the 18-day period, 
showing both the DSS treatment and the recovery/drug treatment. 
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After the 14-day recovery period the mice were culled and colon and bone tissues were 
collected. The right tibia from each mouse was dissected and frozen in dH20 at -20
oC until 
required. The right femur and colon were fixed in 4% paraformaldehyde for 24 hours at 
4oC before being stored in 70% ethanol. The left femur had the ends removed, the bone 
marrow spun out and then the bone was snap frozen in liquid nitrogen and stored at -80oC 
until required. Blood was collected upon death and spun at 1000g for 15 minutes. The 
serum was aliquoted and stored at -80oC until required. 
2.2. Micro computed tomography (µCT) 
The right tibia bone from each mouse was scanned with an 1172 X-Ray microCT 
(Skyscan, Belgium) at 5 µm resolution (60kV, 167µA, 0.5 mm aluminium filter, 0.6° 
rotation angle, two frame averaging, and exposure time 1650). The projection images 
were reconstructed using NRecon software version 1.6.9.4 (Skyscan, Belgium).  
To determine any changes in the bone microarchitecture, the trabeculae in comparative 
regions of interest were examined. The bottom of the growth plate was located as a 
reference on each of the scanned bones. A section of 250 slices was then analysed, at 5% 
of the total bone length beneath the growth plate reference point (Fig. 2.2). Trabeculae 
were isolated using CtAn and using BatMan (Skyscan), changes in trabecular parameters 
were examined: Bone Volume/Tissue Volume (BV/TV, %), Trabeculae thickness (Tb.Th 
mm), Trabeculae pattern factor (Tb.Pf, 1/mm), Number of Trabeculae (Tb.N, 1/mm), 
Bone mineral density (BMD). 
Following the analysis of changes in the trabeculae, changes in the cortical bone were 
also examined. Two sections of 100 slices were selected at 37% and 50% from the top of 
the bone (Fig. 2.2). The cortical bone was highlighted using CtAn and BatMan (Skyscan) 
and changes in the cortical parameters were analysed: Bone Volume/Tissue Volume 
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(BV/TV, %), Tissue Area (T.Ar), Tissue Perimeter (T.Pm), Bone Area (B.Ar) and Bone 
Perimeter (B.Pm), Bone mineral density (BMD). 
 
 
 
 
 
 
 
 
 
 
 
 
2.3. Histological studies 
2.3.1. Tissue processing 
Following tissue dissection and fixation (section 2.3), the left tibia from all mice was 
decalcified in 10% ethylenediaminetetraacetic acid (EDTA) at 4oC for approximately 6 
weeks. Tissue processing, paraffin embedding, and sectioning (5 µm) of the tibia and the 
colon were done following routine procedures. 
Figure 2.2: Scanned image of the tibia bone showing the regions used 
in the analysis of the trabeculae and the cortical bone 
Growth Plate 
5% 250 slices 
37% 100 slices 
50% 100 slices 
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2.3.2 Immunohistochemistry 
A Vectastain ABC kit (Vector Laboratories, Peterborough, UK) was used for the 
immunohistochemical analysis of the samples according to the instructions from the 
manufacturer. The samples were first de-waxed in xylene and then rehydrated through a 
serious of alcohol dilutions from absolute alcohol to distilled H2O. Antigen retrieval was 
carried out using 10 mM citrate buffer (pH 6) for 90 minutes at 70oC in the oven. After 3 
x 5-minute washes in PBS, any endogenous peroxidase activity was blocked by using 
0.3% H2O2 for 30 minutes at room temperature. Following a further 3 x 5 minute PBS 
washes the sections were blocked using the normal blocking buffer for 30 minutes at 
room temperature. The sections were then treated with the primary antibody (see Table 
2.2) diluted in the blocking buffer. The controls were treated with an equal concentration 
of rabbit immunoglobulin G (IgG). All samples were left at 4oC overnight. 
Following the incubation with the primary antibody the samples were washed for 3 x 5 
minutes in PBS before being incubated in the biotinylated secondary antibody for 30 
minutes at room temperature. The sections were then washed again for 3 x 5 minutes in 
PBS before being incubated in the ABC reagent for another 30 minutes at room 
temperature. Before staining the samples were washed in PBS. The sections were then 
stained using diaminobenzidine (DAB) solution for 5 minutes. The samples were then 
rinsed in tap water and counterstained with haematoxylin before being dehydrated 
through ethanol to xylene. The sections were then mounted onto microscope slides using 
DePex and left to dry before microscopic analysis. The immunohistochemical expression 
was quantified using ImageJ software. 
2.3.3. Goldners trichrome staining 
As previously described, the sections were dewaxed and rehydrated to water before being 
stained in wiegert’s haematoxylin for 10 minutes. The slides were then washed for 10 
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minutes before being immersed in Ponceau Acid Fuchsin. The sections were washed in 
1% acetic acid (2 x 5 min) then placed in phosphomolybdic Acid-Orange G solution. The 
sections were washed again in acetic acid (2 x 5min) and placed in the light green stock 
solution. The slides were rinsed in dH20 before being mounted using DePex and left to 
dry before microscopic analysis 
2.3.4. Haematoxylin and eosin (H&E) staining 
The tibia sections were dewaxed and rehydrated in xylene through ethanol before being 
stained in haematoxylin for 8 minutes. The sections were then washed in running tap 
water for 10 minutes before being washed in distilled water. The samples were rinsed in 
90% alcohol before being counterstained in eosin Y solution for 1 minute. Following 
counterstaining the slides were dehydrated through alcohol, mounted with DePex and left 
to dry before microscopic analysis.  
2.3.5. Pathological analysis of the colon 
Colon pathology was graded blind on sections from all 3 segments of each mouse using 
an established histological grading scheme by Prof. Elspeth Milne at the University of 
Edinburgh, following H&E staining (Dieleman et al., 1998). Segments of colon were 
assessed separately for inflammation. Scores from all five segments were averaged to 
provide an overall pathology score.  
2.4. ELISA 
ELISA assays were carried out to test for N-terminal propeptide of Collagen alpha-1(I) 
chain (P1NP) and Fragments of C-terminal telopeptides of Col1a1 (Ctx). P1NP is used to 
monitor bone formation and Ctx is a blood biomarker to assess bone resorption.  
The Mouse P1NP ELISA Kit and Mouse α-CTx ELISA Kit (AMS Bio., UK) were used 
to assess blood samples from the DSS mouse model, according to the manufacturer’s 
instructions. Briefly, the standards and samples were plated into 96-well plates before 
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being incubated at 37oC. For the Ctx, the antibody was added with the sample prior to 
incubation, whereas the P1NP was added following the incubation. Washes were carried 
out using wash buffer before TMB substrate was added to each well stimulating a colour 
change to blue. Stop solution was used causing a yellow colour change before plates were 
immediately read at 450 nm. The concentration of P1NP/ Ctx in the sample was then 
calculated. 
2.5. Cell culture 
Murine MC3T3 osteoblast cells (subclone 14; American Type Culture Collection ATCC, 
USA) were used throughout this study up to passage 16. The frozen cells were removed 
from -150oC storage and were thawed in a water bath at 37oC. These were then transferred 
into a falcon tube with 5 ml of warm medium (αMEM supplemented with 10% foetal 
bovine serum (FBS) (Sigma Aldrich, Germany) and 5% penicillin/streptomycin (Sigma 
Aldrich, Germany) (10,000 units/ml penicillin and 10mg/ml streptomycin). Cells were 
then centrifuged at 136 g for 3 minutes (Hettich Universal 320R) and the supernatant 
discarded. Cells were resuspended in culture medium and placed in a T175 flask 
containing 24 ml of culture medium. The cells were left in an incubator set at 37oC with 
the atmosphere containing 5% CO2 and left to grow over a period of approximately 2-3 
days until a semi-confluent monolayer was formed. 
Once the cells had reached 80% confluency, the media was removed from the flask and 
the cells were wash with distilled water (dH2O) to remove any remaining FBS in the flask. 
Following this, 1% trypsin (Sigma Aldrich, Germany) was used to detach the cells from 
the surface of the flask. The cells were removed from the flask, centrifuged at 136 g for 
3 minutes and the supernatant was disposed of. The pellet was resuspended in culture 
media and the cells were counted using a haemocytometer. The cells were then plated 
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into 6 well plates at 1x105 cells per well and cultured to confluency as described in section 
2.2.  
2.6. Cell treatment 
When the MC3T3 cells had reached 100% confluency (approx. 72hrs) the cells were 
treated with 50 µg/ml ascorbic acid, to assist in the production of the matrix, and 5 mM 
beta-glycerophosphate (βGP), to act as a phosphate source for bone mineralisation for a 
10-day period. The cells were then treated for 24 hours with 120 µM azathioprine 
(TOCRIS, UK) or 10 µM rapamycin (Cell Signalling, UK) as the positive control. The 
negative control was treated with equal concentrations of dimethyl sulfoxide (DMSO) 
(Sigma Aldrich, Germany). Additionally, an autophagy control (80 nM bafilomycin 
(Santa Cruz Biotechnology, USA)) was also included with the positive control and the 
azathioprine test group. Concentrations used were based on previous optimisation 
experiments from the research group (Singha et al., 2008). The cells were left to incubate 
for 24 hours before being scrapped for RNA and protein.  
2.7. RNA methods 
2.7.1. Extraction of RNA from cells 
Cells were scraped with 1 ml of cold PBS, centrifuged to form a pellet and stored 
overnight at -80oC. The RNA was then extracted using the Qiagen RNeasy Kit (Qiagen, 
Manchester, UK), following the manufacturer’s instructions. The cells were first 
homogenised in the RLT buffer before adding 70% ethanol to allow for the binding of 
RNA precipitates to the membrane. Buffers and centrifugation were used to remove any 
contaminants. The RNA was then collected using RNase free water. The amount of RNA 
collected in ng/µl was measured using a NanoDrop spectrophotometer 
(ThermoScientific, Paisley, U.K). The purity of the samples was measured using the ratio 
of absorbance’s at 260/280 wavelengths, and values between 1.8 and 2.1 were used as 
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optimal. The samples were then diluted using RNase free water and stored at -80 oC for 
future use. 
2.7.2. Reverse transcription 
cDNA was obtained from the RNA samples by performing reverse transcription using the 
Precision nanoscript2 Reverse Transcription kit (Primerdesign, UK). RNA was diluted 
with RNAse free water to equal the lowest concentration among the samples and added 
to 1 µl Oligo-dT primer. Following heat at 65oC for 5 minutes, the samples were cooled 
on ice before the addition of the mastermix. The mastermix consists of RNAse free water, 
nanoscript2 enzyme, nanoscript2 reaction buffer and dNTP mix. The samples were 
further heated at 42oC then 75oC for 30 minutes and diluted with RNAse free water to the 
concentration of 5 ng/µl. 
2.7.3. Real-time polymerase chain reaction (RT-qPCR) 
The cDNA samples were diluted to 5 ng/µl with RNase free water. A master mix was 
made up containing 10 µl qPCR master mix with SYBR green (Primerdesign, UK), 4µl 
of RNase free water and 1 µl of the appropriate primers (see Table 2.1). This was added 
to 5 µl of diluted cDNA and loaded into a StepOne Real-Time PCR system 
(ThermoFisher Scientific, UK). The cycle threshold (Ct) values obtained were normalised 
to Atp5b in MC3T3 cell lines and the expression of each gene was calculated using the 
2ΔCt method (Livak & Schmittgen, 2001). 
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2.8. Protein methods 
2.8.1. Protein extraction 
The cell monolayers were washed with PBS before being scraped with 200µl of 
Radioimmunoprecipitation assay (RIPA) buffer (Thermoscientific, UK), containing 
protease inhibitor cocktail (Roche, Germany). The cell monolayer was scraped with a 
sterile cell scraper and transferred to a sterile Eppendorf. The samples were vortexed and 
stores at -20oC for future analysis. The samples were frozen at -20oC for future use. 
2.8.2. DC protein assay 
The concentration of protein in each sample was determined using a detergent compatible 
(DC) assay (Bio-Rad, Watford, UK). The samples were defrosted and vortexed at full 
speed for 5 minutes. Five microliters of the samples were pipetted in triplicate in a 96-
well plate alongside known protein standards. Twenty-five microliters of Bio-Rad DC 
protein assay Reagent A and 200 µl Bio-Rad DC protein assay Reagent B was added to 
all samples and standards and the plate was left to incubate for 15 minutes. The 
absorbance was analysed using a microplate reader at 750 nm. The concentration of each 
protein samples was determined using the standard curve produced from the standards. 
Gene of Interest Source S Sequence (5’-3’)
BGLAP Primer Design Forward TGCACGAAAGCAAGATGCTG
Reverse GGAGCGTCTGAATAGTCGCC
Postn Primer Design Forward TTCCTCTCCTGCCCTTATATGC
Reverse CCTGATCCCGACCCCTGAT
COL1A1 Primer Design Forward GCTCCTCTTAGGGGCCACT
Reverse CCACGTCTCACCATTGGGG
ATP5B Primer Design Forward Not disclosed
(Housekeeping) Reverse Not disclosed
Table 2.1. Primers used for RT-qPCR analysis. 
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2.8.3. Western blotting 
Protein was denatured in a heat block at 70oC for 10 minutes. An equal concentration of 
protein (30 µg) was loading into a 4-12% Bis Tris protein gel (NuPAGE, Life Tech., UK), 
which was then loaded into an electrophoresis tank (Xcell Surelock, Invitrogen, UK) 
containing MES SDS running buffer. To preserve the proteins, antioxidant (NuPAGE, 
UK) was added to the central chamber and electrophoresis was ran at 200V for 50 
minutes.  
The protein was transferred to a PVDF (Polyvinylidene fluoride) membrane (Sigma 
Aldritch, Germany). The PVDF membrane was sandwiched between filter paper and 
sponges previously soaked in transfer buffer creating a wet transfer. The transfer was 
carried out on ice at 30V for 70 minutes. The PDVF membrane was blocked in odyssey 
blocking buffer (Licor, Nebraska, US) for 1 hour at room temperature before being 
incubated with the appropriate primary antibody (see Table 2.2) overnight at 4 oC. 
The primary antibody was washed off in PBST (3 x 10min) at room temperature then 
incubated for a further 1 hour in the species appropriate secondary antibody (see Table 
2.2) diluted in Odyssey buffer. The PDVF membrane was again washed in PBST (3 x 
10min). The proteins were then detected using the Licor system (Licor, Nebraska, US). 
 
 
Table 2.2. Primary antibodies for western blot and immunohistochemistry 
Antibody Species Source Use Dilution
LC3 Rabbit Cell signalling Western Blot 1 in 1000
LC3 Rabbit MBL IHC 1 in 500
p62 Rabbit Abcam Western Blot 1 in 1000
p62 Rabbit Abcam IHC 1 in 500
Actin Goat Santa Cruz Biotech Western Blot 1 in 1000
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2.8.4. Stripping PVDF membrane for additional western blotting 
The PVDF membrane was stripped in mild stripping buffer containing glycine and SDS 
(pH 2.0). The membrane was placed in the stripping buffer for 3 x7min incubations before 
being rinsed in distilled water to remove residual buffer. The membrane was then washed 
in PBST (3 x 5min). The membrane was then re-blocked with odyssey buffer and probed 
with a different antibody. 
2.9. Statistical analysis  
Data are presented as mean ± S.E.M. where P<0.05 was considered to be significant. Data 
analysis was carried out using GraphPad Prism 6 (GraphPad Software, Inc, USA). 
Differences between treatment groups were assessed by one-way analysis of variance 
(ANOVA) for which tests for multiple comparisons were conducted. Tukey and 
Bonferroni tests were carried out to correct for multiple testing between groups for the in 
vivo results.  
Table 2.3. Secondary antibodies for western blot and immunohistochemistry 
Antibody Source Use Dilution
Goat anti-rabbit Licor Western Blot 1 in 1250
Rabbit anti-goat Licor Western Blot 1 in 1250
Goat anti-rabbit Vector Lab Immunohistochemistry 1 in 10,000
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3.1. Introduction 
Osteoporosis can be a  secondary effect to a number of gastrointestinal conditions, 
including IBD (Ali et al., 2010). Osteoporosis is a metabolic disease of the bone 
characterised by a reduction in bone mineral density and alterations in bone structure 
(Bianchi, 2010). Osteoporosis increases the likelihood of bone fracture in the individual. 
Indeed patients with IBD are 40% more at risk of bone fracture than a healthy individual 
(Ali et al., 2010). 
Bone loss in IBD is thought to be caused by two main factors, malabsorption and 
inflammation (Bianchi, 2010). Intestinal absorption of key determinants of bone health – 
e.g. Ca2+ and vitamin D - is often altered in IBD due to the reduction of intestinal mucosa 
(Bianchi, 2010). IBD is also characterised by the chronic release of pro-inflammatory 
cytokines such as IL-7 and tumour necrosis factor-α (TNF-alpha) - the increased 
production of these cytokines can stimulate bone resorption by osteoclasts which 
therefore leads to excessive bone loss (Bianchi, 2010: Shen, 2004). However, other 
mechanisms may exist and the development of targeted therapies for this bone loss 
requires a better understanding of the underlying cellular mechanisms.  
Drugs used to treat IBD include steroids, immunosuppressants, aminosalicylates (5-
ASAs) and biologic agents. There is an increasing demand to optimise existing medical 
therapies through patient stratification and personalised medicine (Denson, 2013). It has 
been previously shown that drugs currently used for IBD can affect autophagy (Hooper 
et al., 2019)., an essential self-eating process that allows the degradation of intracellular 
components such as organelles, foreign bodies and soluble proteins through the formation 
and maturation of double membrane vesicles, known as autophagosomes (Yu et al., 
2017). Specifically, it was shown that the thiopurine azathioprine is a potent autophagy 
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inducer in peripheral blood mononuclear cells (Hooper et al., 2019), however its effects 
on bone health has yet to be established.  
The dextran sulphate sodium (DSS) mouse model is utilised in this study. DSS is thought 
to induce colitis through a toxic effect on the intestinal cells. It has been found previously 
that treatment with DSS causes changes in bone structure and can cause bone loss. DSS-
induced colitis has been linked with a reduction in bone mass and changed micro 
architecture. This is caused by suppressed bone formation and increased bone resorption 
(Hamdani et al., 2008; Dobie et al., 2018). 
Therefore, in this chapter, I aimed to establish the effects of azathioprine on bone health 
by using the (DSS) model of IBD in mice.  
3.2. Materials and methods 
3.2.1 Animal model 
In the DSS model, 24 male 10-week old C57BL/6J WT mice were treated with either 3% 
DSS-treated or regular water ad libitum for 4 days, following which they were given 
normal tap water for a 14-day recovery period (see section 2.1). Mice were treated daily 
by oral gavage with 10 mg/kg/day of azathioprine or a vehicle control (n=6/group). After 
the 14-day recovery period, the mice were culled and blood, colon and bone samples 
collected (see section 2.1). Control mice (non-DSS treated), receiving the vehicle control 
or azathioprine were treated with normal tap water for the duration of the study. 
3.2.2 Colon phenotyping 
Following dissection, the colon of all mice was fixed in 4% paraformaldehyde for 24 
hours at 4oC before being stored in 70% ethanol. Tissue processing, paraffin embedding, 
and sectioning (5 µm) of the colon was done following routine procedures (see section 
2.3.1). Colon pathology was graded blind on H&E stained sections using an established 
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histological grading scheme by Prof. Elspeth Milne at the University of Edinburgh, 
following (see section 2.3.6). 
3.2.3 Bone phenotyping 
Following dissection, the right tibia bone from each mouse was scanned with an 1172 X-
Ray microCT (Skyscan, Belgium) at 5 µm resolution. Changes in trabecular 
microarchitecture and cortical geometry were determined using established methods (see 
section 2.2). The left tibia from all mice was decalcified in 10% EDTA following fixation, 
and tissue processing, paraffin embedding, and sectioning (5 µm) conducted following 
routine procedures (see section 2.3.1). Histological staining was carried out as described 
in sections 2.3.2 – 2.3.5. ELISA analysis of bone formation (P1NP) and bone resorption 
(Ctx) were conducted on serum collected from all mice (see section 2.4).  
3.3. Results 
3.3.1 The effect of DSS treatment on body weight and longitudinal 
bone growth of mice 
 
Figure 3.1: Percentage change in body weight of azathioprine and vehicle treated 
10-week old WT mice treated with or without 3% DSS for 4 days. Data are 
presented as mean ± S.E.M (n=6/group).  
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To assess the effects of DSS-induced colitis, azathioprine and vehicle treated mice were 
given 3% DSS for 4 days. The dose and duration of the DSS treatment was based on 
previous studies using the same mouse strain (Dobie et al., 2018). During the DSS 
treatment period (0-4 days), no significant weight loss was observed in any mouse 
treatment groups (Fig. 3.1). Independent of azathioprine treatment, mice exhibited a rapid 
and significant weight loss from day 4 following DSS treatment (up to 7% in comparison 
to non-DSS (water) treated mice, P<0.0045). Following this period of weight loss, 
DSS/vehicle treated mice continued to gain weight to the end of the study, similar to the 
water/vehicle treated mice (Fig. 3.1). However, after an initial weight gain following the 
period of weight loss, DSS/azathioprine treated mice plateaued in their weight gain from 
day 10 onwards (Fig. 3.1). Similarly, water/azathioprine treated mice showed no 
significant weight gain throughout the experiment (Fig. 3.1). Full details of the weight 
measurements over the 18-day treatment period can be seen in Appendix Table 1. DSS 
treatment in vehicle and azathioprine treated mice had no effect on tibia length (Table 
3.1). 
 
         Vehicle Treated    Azathioprine treated 
  Water DSS treated Water  DSS treated 
Tibia (mm) 17.3 ± 0.1 17.4 ± 0.1 17.1 ± 0.2  17.4 ± 0.1 
Table 3.1: Tibia length measurements of vehicle and azathioprine 
treated 10-week old WT mice at day 18 of DSS study. Data are 
presented as mean ± S.E.M (n=6/group). 
a
 significantly different 
from vehicle treated control mice (P<0.0003*).  
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3.3.2. Colon pathology in DSS-treated mice 
 
Water + Vehicle DSS + Vehicle 
Water + 
Azathioprine 
DSS + 
Azathioprine 
A 
E 
D C 
B 
Figure 3.2: Colon pathology of azathioprine and vehicle treated 10-week old WT mice 
treated with 3% DSS. Histological scoring of colons (A) Inflammation severity score (B) 
Inflammation extent score (C) Regeneration score (D) Crypt damage score (E) 
Representative H&E-stained sections of colon. Data are presented as mean ± S.E.M 
(n=6/group). P<0.05*, P<0.01**. Scale bar = 100 µm.  
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To assess the effects of DSS on mucosal integrity, detailed histological analysis was 
performed on the colon from water and DSS-treated vehicle and azathioprine-treated 
mice. Histological scores for all parameters were minimal in the non-DSS treated (water) 
mice, and there were no notable differences observed with azathioprine treatment in this 
group (Fig. 3.2). In contrast, histological analysis of the colon from DSS-treated mice 
revealed significant increases in inflammation severity (Fig. 3.2A, P<0.0076) and extent 
(Fig. 2B, P<0.0059) scores in comparison to water treated mice, consistent with previous 
studies and indicative of colitis induction. It was also observed that treatment with 
azathioprine in the DSS model provides partial protection to the colon through increased 
tissue regeneration (Fig. 3.2C) and no significant effect on the crypt damage score (Fig. 
3.2D), in contrast to the vehicle treated mice (P<0.0077). 
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   3.3.3. Bone phenotype of DSS treated mice 
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Figure 3.3: Trabecular bone micro-architecture of azathioprine and vehicle treated 10-
week old WT mice treated with 3% DSS. (A) Representative 3D µCT reconstructions. 
Trabecular bone parameters between treated and control groups (B) Bone volume/tissue 
volume (BV/TV), (C) Trabecular thickness (TB.Th), (D) Trabecular pattern factor 
(Tb.Pf), (E) Trabecular number (Tb.N), (F) Tibia length (mm), (G) Bone mineral density. 
Data are presented as mean ± S.E.M (n=6/group). P<0.05*.  
G 
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DSS-induced colitis has previously been shown to have detrimental effects on bone 
quality (Dobie et al., 2016; Hamdani et al., 2008; Harris et al., 2009). In accordance with 
these studies, DSS/vehicle treated mice showed worsened trabecular microarchitecture 
compared to water/vehicle treated mice as demonstrated by μCT (Fig. 3.3). Thus, 
confirming DSS induced the expected colitis-mediated effects on bone health. 
Specifically, DSS/vehicle treated mice exhibited a significant decrease in trabecular 
thickness (Fig. 3.3C, P<0.0003) compared to the water group, with further decreases in 
BV/TV (Fig. 3.3B, P<0.0141), and, although not significant, trabecular number (Fig. 
3.3E) also observed. Treatment with azathioprine appeared to provide partial protection 
against the DSS-induced bone loss as trabecular thickness was significantly increased in 
comparison to the vehicle treated DSS mice (Fig. 3.3C, P<0.0136). However, this 
protection was not observed in any of the other parameters. 
Most interestingly, azathioprine treatment alone had a significant detrimental effect on 
the bone health of mice, independent of DSS treatment. Indeed, significant decreases were 
observed in BV/TV (Fig. 3.3B, P<0.0003), and trabecular number (Fig. 3.3E, P<0.0011), 
with a concurrent significant increase in trabecular pattern factor (Fig. 3.3D, P<0.0042) 
indicative of a more disorganised trabecular structure.  
The cortical bone was examined by μCT however there was no significant differences 
observed in any parameters between the treatment groups (Fig. 3.4). Histological analysis 
of the tibia sections confirmed the results seen from the µCT analysis with a reduction in 
bone volume (indicated by increased red osteoid staining) in the trabecular bone in both 
the DSS treated mice and those threated with azathioprine (Fig. 3.5A). Similarly, little 
differences were observed in the cortical bone (Fig. 3.6A). 
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Figure 3.4: Cortical bone geometry of azathioprine and vehicle treated 10-week 
old WT mice treated with 3% DSS. (A) Representative 3D µCT reconstructions. 
Cortical bone parameters between treated and control groups (B) Bone 
volume/tissue volume (%BV/TV), (C) Bone area (B.Ar), (D) Tissue area (T.Ar), 
(E) Bone perimeter (B.Pm) and (F) Tissue perimeter (T.Pm). (G) Bone mineral 
density. Data are presented as mean ± S.E.M (n=6/group).  
G 
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Figure 3.5: Histological staining of tibial trabecular bone in sections 
of the tibia of 10-week old WT mice. (A) Goldner’s trichrome (B) 
H&E. An increase in osteoid can be seen due to the higher intensity of 
pink staining within the trabecular bone as a result of azathioprine 
treatment (arrows) indicating a reduction in bone volume. This 
reduction in bone volume is also observed in the DSS control group. 
Scale bar = 50µm. Images are representative of 4 different mice/group. 
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Figure 3.6: Histological staining of tibial cortical bone in sections of the 
tibia in 10-week old WT mice. (A) Goldner’s trichrome (B) H&E. There 
was no changes observed in the cortical bone stains indicating minimal 
change to bone volume. Scale bar = 50µm. Images are representative of 
4 different mice/group. 
A 
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3.3.4. ELISA 
 
 
 
 
 
 
 
 
 
ELISA assays were carried out to test for the bone formation and resorption markers, 
P1NP and Ctx respectively. 
Unfortunately, there was found to be no significant changes between treatment groups in 
the serum concentration of Ctx (bone resorption) (Fig. 3.9A) or P1NP (bone formation) 
(Figure 3.9.B)  
 
 
 
 
 
Figure 3.7: ELISA analysis of (A) Bone resorption (Ctx) and (B) Bone 
formation (P1NP) markers in the serum of vehicle and azathioprine 
treated DSS 10-week old WT mice. Data are presented as mean ± S.D 
A B 
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3.4. Discussion 
It is thought that increased inflammation leads to bone loss in IBD patients due to 
malabsorption of nutrients such as vitamin D and calcium (Bianchi, 2010). However, 
other direct mechanisms may exist and the development of targeted therapies for this bone 
loss requires a better understanding of the underlying cellular mechanisms. Therefore, in 
this chapter, I aimed to examine the effects of the commonly prescribed IBD drug 
azathioprine on bone health in an in vivo model of IBD, due to the known effects of 
azathioprine on autophagy.  
Osteoporosis is a metabolic disease of the bone which is characterised by a reduction in 
bone mineral density and alterations in bone structure (Bianchi, 2010). It is seen as a 
secondary symptom of IBD and patients who suffer from IBD often experience bone loss 
and are 40% more likely to suffer from fractures compared to healthy individuals (Ali et 
al., 2010). DSS-induced colitis has previously been shown to have detrimental effects on 
bone quality (Dobie et al., 2018; Hamdani et al., 2008; Harris et al., 2009). In accordance 
with these studies, the model used here showed the expected worsened bone trabecular 
microarchitecture with DSS treatment in mice. 
Here it was found that azathioprine provided partial protection against bone loss in IBD 
as there was significantly increased trabecular thickness in comparison to vehicle treated 
mice, although this was not observed in any of the other parameters. However, when 
azathioprine was administered alone it was found to be detrimental to bone 
microarchitecture in comparison to the vehicle control, as indicated by the significant 
reductions in both the overall bone volume, the number of the trabeculae as well as 
increased trabecular disorganisation (trabecular pattern factor).  
The treatment with thiopurines such azathioprine and 6-mercaptopurine has previously 
been found to be negatively associated with height in children with crohn’s disease. It 
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was observed that thiopurines were linked to a reduction in lean tissue mass, weight and 
BMI scores in pediatric CD patients (Gupta et al., 2018). This compliments the findings 
in this study where it was observed that the tibia length of mice treated with azathioprine 
was reduced indicating that the use of thiopurine treatment may result in reduced growth 
in patients. 
Azathioprine has previously been linked to an increase in fracture risk in humans. 
However fracture risk was not in increased in common osteoporotic sites such as the hip 
or spine, but rather an increase in the overall skeletal fracture risk was observed 
(Vestergaard et al., 2006). In addition, it has been suggested that azathioprine can disrupt 
the bone remodelling process by suppressing T lymphocytes causing disturbances in the 
RANKL system responsible for osteoclast differentiation (Cegiela et al., 2013). Cegiela 
et al., found that although the length and diameter of the bones remained unchanged, 
azathioprine caused an overall reduction in femur and tibia mass in a rat model, whilst 
also reducing the calcium content. Further, the thickness of the trabeculae in the femur 
was found to be reduced in rats when treated with azathioprine in both the distal epiphysis 
and metaphysis (Cegiela et al., 2013). These findings complement my findings that the 
administration of azathioprine may contribute to overall bone loss and trabecular bone 
deterioration. This suggests that azathioprine alone may therefore not be a suitable drug 
of choice in IBD patients who are more at risk of osteoporotic bone fractures, such as the 
elderly. 
Histopathological analysis of the colon revealed successful induction of colitis in DSS 
treated mice, however also revealed no differences in the severity or extent of 
inflammation in azathioprine treated mice, in comparison to vehicle-treated mice. This 
therefore suggested that the effects of azathioprine are direct on the skeleton in IBD. It 
has previously been found that azathioprine induces autophagy in peripheral blood 
mononuclear cells and colorectal cancer cells (Hooper et al, 2019; Chaabane & Appell, 
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2016). In addition, autophagy has previously been found to play a protective role in bone 
health and when autophagy becomes dysregulated it can have a harmful effect on bone 
(Pierrefite-Carle et al., 2015). However, the effect of azathioprine on autophagy in bone 
has yet to be determined. 
In conclusion, the data detailed in this chapter show that although azathioprine may 
provide partial protection against bone loss in IBD, it was found to cause detrimental 
effects when administered to a healthy control group. Because of this the mechanism of 
action of azathioprine needs to be better understood, to allow for better quality of 
treatment for IBD patients. 
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4.1. Introduction 
The administration of azathioprine to the murine DSS model detailed in chapter 3 
revealed detrimental effects on the skeleton in both the healthy mice and those with 
colitis. Due to the lack of changes in the severity or extent of colon inflammation with 
azathioprine treatment, this may suggest that the detrimental effects on the skeleton may 
occur as a direct result of treatment. It has been previously shown that azathioprine 
induces autophagy in peripheral blood mononuclear cells and colorectal cancer cells 
(Hooper et al, 2019; Chaabane & Appell, 2016). Therefore, we hypothesised that 
autophagy may be induced in the skeleton as a survival mechanism to compensate the 
adverse effects caused by azathioprine treatment. 
Autophagy involves the removal of  damaged  organelles or proteins from the cell (Shen 
et al., 2018). The process begins with the formation of a phagophore which engulfs the 
cargo destined for degradation, thereby forming the autophagosome. The autophagosome 
then binds with a lysosome in the cell cytoplasm where the contents are degraded via 
lysosomal hydrolases. The degradation products  are then released back into the 
cytoplasm and recycled (Aburto et al., 2012). 
A complex is formed on the phagophore which includes LC3, the mammalian homologue 
of Atg8, which is found on both the outer and inner membranes of the autophagosome. 
There are two forms of LC3 - LC3I and LC3II. During the induction of autophagy, LC3-
I is converted to LC3II by the cleaving of LC3I by Atg4 to allow for the conjunction to 
phospholipids. This is essential for the formation of the autophagosomes (Iii et al., 2010, 
Glick et al., 2010) and LC3 is therefore a dependable way to monitor autophagy activity 
as the amount of LC3-II correlates with the number of autophagosomes. p62 is an adaptor  
protein that is  degraded by  autophagy due to its binding with LC3 (Lilienbaum, 2013). 
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Therefore, when autophagy is disrupted, levels of p62 increase and therefore p62 can be 
a good marker of autophagy activation (Duran et al., 2016). 
A number of studies have found that the activation of autophagy is beneficial for bone 
health. It has previously been shown that autophagy is increased during osteoblast 
differentiation and ECM mineralisation, and that the inhibition of autophagy reduces 
ECM mineralisation (Pierrefite-Carle et al., 2015). Further, there are a number of studies 
suggesting that autophagy induction may protect against bone loss in osteoporosis (Zahm 
et al., 2011). However, the role of autophagy in IBD-related osteoporosis has yet to be 
established. 
Therefore, in this chapter, I aimed to establish the effects of azathioprine on autophagy in 
the skeleton in the (DSS) model of IBD in mice, and to characterise the effects of 
azathioprine on an in vitro osteoblast cell culture model.  
 
4.2. Materials and methods 
4.2.1. Tissue processing and immunohistochemistry 
Following tissue dissection and fixation (section 2.3.1), the left tibia from all mice was 
decalcified in 10% EDTA. Tissue processing, paraffin embedding, and sectioning (5 µm) 
of the tibia was done following routine procedures. Immunohistochemical labelling for 
LC3 and p62 (see Table 2.2 & 2.3) was carried out using a Vectastain ABC kit, according 
to the manufacturer’s instructions (section 2.3.2). The immunohistochemical expression 
was quantified using ImageJ software. 
4.2.2. Cell culture and treatment 
Murine MC3T3 osteoblast-like cells were cultured in αMEM supplemented with 10% 
FBS and 5% penicillin/streptomycin. Cells were plated into 6 well plates at 1x105 cells 
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per well (section 2.5) until confluency at which point they were cultured for up to 10 days 
with the addition of 50 µg/ml ascorbic acid and 5 mM βGP (section 2.6). The cells were 
then treated for 24 hours with 120 µM azathioprine or 10 µM rapamycin as the positive 
control. Additionally, 80 nM bafilomycin was also included with the positive control and 
the azathioprine test group. Bafilomycin induces autophagosome accumulation by 
blocking the fusion of autophagosomes and lysosomes helping to measure autophagy as 
it results in an accumulation of LC3.  The cells were left to incubate for 24 hours before 
being scrapped for RNA and protein. 
4.2.3. RNA analysis of MC3T3 cells 
RNA was isolated from MC3T3 cells using a Qiagen RNeasy kit (section 2.7.1) and 
reverse transcribed to cDNA (section 2.7.2). For qPCR analysis, cDNA was diluted to     
5 ng/µl using RNase free water and analysed using a StepOne Real-Time PCR system. 
The cycle threshold (Ct) values obtained were normalised to Atp5b in MC3T3 cell lines 
and the expression of osteoblast genes (Table 2.1) were calculated using the 2ΔCt method 
(Livak & Schmittgen, 2001).  
4.2.4. Protein extraction and western blot 
Proteins were extracted from MC3T3 cells at 24 hours in RIPA buffer as described in 
section 2.8.1. Protein samples were quantified using a DC assay (section 2.8.2) and 
prepared for western blot analysis. Proteins were loaded on a 4-12% Bis Tris protein gel 
and then transferred to PVDF membrane. The membrane was blocked using Odyssey 
buffer before being probed for the autophagy markers LC3 and p62 (Tables 2.2 & 2.3). 
Following exposure to an appropriate secondary antibody, proteins were detected using 
the Licor system. Protein loading was confirmed by re-probing the membrane with actin 
antibody (1:1000). 
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4.3. Results 
4.3.1. Autophagy induction in azathioprine treated mice 
To examine whether azathioprine affects autophagy in vivo, immunohistochemistry for 
the autophagy markers LC3 and p62 were conducted.  
Increased LC3 labelling was observed in azathioprine treated bones vs vehicle treated 
(Fig. 4.1A, Fig. 4.3A & B), independent of DSS treatment. Specifically, LC3 was found 
in the osteoblasts lining the trabecular bone, in the osteocytes, and throughout the bone 
marrow. Increased LC3 labelling was also observed in the osteoblasts lining the cortical 
bone compared to those treated with the vehicle (arrows, Fig. 4.2A, Fig. 4.3A). The DSS 
treatment alone was not successful in inducing autophagy however the treatment with 
azathioprine in the DSS group produced increased LC3 labelling in both trabecular and 
cortical bone (Fig. 4.1A, 4.2A & 4.3A & B). p62 levels were low in almost all treatment 
groups apart from an increase in the cortical bone in the two vehicle control groups (Fig. 
4.1B & 4.2B, 4.3C & D). Together, this indicates that autophagy is induced by 
azathioprine in vivo, independent of DSS treatment. IgG labelling was utilised as a control 
in all IHC experiments (Appendix 2). 
 
 
 
Chapter 4: The effects of azathioprine on autophagy in bone 
 59  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p62 IHC LC3 IHC 
Figure 4.1: Immunohistochemical labelling of tibial trabecular bone in 
sections of the tibia in 10-week old WT mice. (A) LC3 immunolabelling 
(B) p62 immunolabelling. LC3 labelling can be seen in both azathioprine 
treatment groups in osteoblasts throughout the bone marrow (arrows). 
P62 can be observed in free osteoblasts aswell as those lining the 
trabecular bone (arrows). Scale bar = 50 µm. Images are representative 
of 4 different mice/group. 
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p62 IHC LC3 IHC 
Figure 4.2: Immunohistochemical labelling of tibial cortical bone in 
sections of the tibia in 10-week old WT mice. (A) LC3 immunolabelling 
(B) p62 immunolabelling. LC3 labelling can be observed in both 
azathioprine treatment groups in osteoblasts lining the cortical bone 
(arrows).There was no changes in the p62 expression in the cortical bone 
between any of the treatment groups. Scale bar = 50 µm. Images are 
representative of 4 different mice/group. 
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4.3.2. Effect of azathioprine treatment on osteoblasts 
Azathioprine was found to have detrimental effects on bone health in the in vivo model 
whilst also inducing autophagy in the skeleton of both the healthy group and the group 
with DSS-induced colitis. We therefore next attempted to examine the effects of 
azathioprine on bone markers and autophagy induction in an osteoblast cell line. MC3T3 
cells were treated with 120 µM azathioprine or 10 µM rapamycin (positive control for 
Figure 4.3: Quantification of immunohistochemical labelling in sections of 
the tibia using ImageJ software. A) LC3 labelling in cortical bone, B) LC3 
labelling in trabecular bone, C) p62 labelling in cortical bone, D) p62 
labelling in trabecular bone.    
A B 
C D 
Chapter 4: The effects of azathioprine on autophagy in bone 
 62  
 
autophagy induction). Bafilomycin was also used in combination with both treatments as 
it results in the augmentation of LC3-II by blocking the fusion of the autophagosome to 
the lysosome (Yamamoto et al., 1998).  
A modest increase in autophagy was observed in the MC3T3 cells treated with 
azathioprine and rapamycin in combination with bafilomycin, as indicated by the 
increased LC3-II expression in comparison to the control observed by western blot (Fig. 
4.4A & B).  This was also detected with treatment of azathioprine alone, however, this 
was not observed in the cells treated with rapamycin (Fig. 4.4A & B). There were little 
changes in LC3-I expression between treatment groups (Fig. 4.4A). The observed 
reduction in p62 protein expression also suggests that autophagy was induced in MC3T3 
cells treated with azathioprine and rapamycin in combination with bafilomycin (Fig. 4.4A 
& C). 
There were no significant changes seen in the mRNA expression of the bone turnover 
markers osteocalcin (Bglap), collagen type I (Col1a1) and periostin (Postn) in 
azathioprine or rapaymcin treated MC3T3 cells in comparison to control cultures by RT-
qPCR (Fig. 4.5). Although no significant changes were observed there was a large 
increase in periostin expression in both groups treated with azathioprine and rapamycin 
alone (Fig. 4.5C). This may indicate that the modest effects on autophagy observed with 
this treatment regime may result in protection against bone damage caused by IBD due 
to the ability of periostin to increase the adhesion capacity of osteoblast cells to matrix 
proteins.   
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Figure 4.4 The effect of Azathioprine on protein expression of LC3 and p62 
in MC3T3 cells after 24 hour exposure to 120 μM Azathioprine, 10 μM 
Rapamycin, vehicle control, and Azathioprine and Rapamycin in 
combination with 80 nm Bafilomycin. A) The western blot results showing 
the expression of LC3 and in response to different treatments. Actin was 
used as a control in all western blot experiments. The Western blots were 
quantified using ImageJ software and the data are presented for B) LC3 
signal intensity & C) p62 signal intensity. 
C
o
n
tr
o
l (
D
M
SO
) 
A
za
/B
fl
 
R
ap
a/
B
fl
 
A
za
th
io
p
ri
n
e 
R
ap
am
yc
in
 
B
af
ilo
m
yc
in
 
LC3-II 
LC3-I 
p62 
Actin (loading control) 
A 
B C 
Chapter 4: The effects of azathioprine on autophagy in bone 
 64  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 The effect of azathioprine on the mRNA expression of (A) Bglap 
(B) Col1a1 (C) Postn in MC3T3 cells after 24 exposure to 120 μM 
azathioprine, 10 μM rapamycin, vehicle control, and azathioprine and 
rapamycin in combination with 80 nM bafilomycin (BFL). D) Fold changes for 
Col1a1, Postn & Atp5b. Results were normalised to Atp5b housekeeping. Data 
are presented as mean ± SEM for n>5.  
A 
B C 
Average Fold Change
Treatment Col1a1/Atp5b Postn/Atp5b Bglap/Atp5b
DMSO 1 1.00000017 1
Bafilomycin 0.044034421 0.23487426 0.58999312
Rapamycin 0.702689781 8.31315588 1.47692375
Azathioprine 0.352056716 4.62210883 0.23467897
Rapamycin/bafilomycin 0.295674096 1.56971124 0.66002981
Azathioprine/Bafilomycin 0.004668091 0.5681969 0.86697526
D 
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4.4. Discussion 
We hypothesised that autophagy may be induced in the skeleton as a survival mechanism 
to compensate the adverse effects caused by azathioprine treatment. Azathioprine has 
already been shown to induce this process in peripheral blood mononuclear cells and 
colorectal cancer 9kcells (Hooper et al, 2019; Chaabane & Appell, 2016).  
Autophagy maintains homeostasis through protein degradation and the use of destroyed 
cell organelles for new cellular formation (Hocking et al., 2012). Upon the induction of 
autophagy,  LC3-I becomes lipidated and becomes LC3-II (Nollet et al., 2014) and 
because of this, the detection of LC3 is a reliable marker of autophagy detection. In this 
study it can be clearly seen that autophagy has been induced in the skeleton by 
azathioprine in both the group with DSS induced colitis and the healthy group. Therefore, 
we have demonstrated, for the first time, that azathioprine is an effective inducer of 
autophagy in the bone. This was confirmed by p62 labelling which was reduced in both 
groups that received azathioprine treatment. p62 is thought to act as a cargo receptor 
during autophagy and is degraded during the binding to LC3 which allows the cargo to 
be enclosed by autophagosomes (Lamark et al., 2009: Itakura & Mizushima, 2011).  
Together, these data indicate that azathioprine can induce autophagy in the skeleton of 
both healthy mice and those with DSS induced colitis. The reasons for this are currently 
speculative as it is currently not known whether autophagy is indirectly induced as a 
survival mechanism to cope with the adverse effects caused by azathioprine on bone 
health. Similarly, because azathioprine does not protect against IBD-induced bone 
deterioration as effectively as predicted, the mechanism of azathioprine action needs to 
be better understood before a better level of care for patients can be provided.  
The main function of osteoblasts is to synthesize and mineralise the osteoid for bone 
formation (Brandi, 2009). There are many known markers of the osteoblast phenotype 
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including osteocalcin (Bglap), periostin (Postn) and collagen type 1 (Col1a1) (Florencio-
Silva et al., 2015, Garnero, 2009). Osteocalcin is a non-collagenous, vitamin K-dependant 
protein that is produced by osteoblasts and an abundance promotes the deposition of 
mineral substance (HA) (Razzaque, 2011). Periostin is an extracellular matrix protein 
highly expressed in collagen-rich tissues and is involved in tissue remodelling and its 
altered function is associated to numerous pathological processes (Cobo et al., 2016). 
Collagen type 1 is secreted by osteoblasts and acts as the scaffold for the deposition of 
hydroxyapatite crystals in bone mineralisation (Van Dijk et al., 2010: Nudelman et al., 
2010).  
The effects of azathioprine on osteoblast function are currently unknown, however, the 
effects of rapamycin are well documented, albeit somewhat controversial in their 
findings. It has been shown that rapamycin, in the presence of lipopolysaccharides, can 
promote the differentiation of human embryonic stem cells (hESCs) into mature 
osteoblasts by modulating mTOR signalling (Lee et al., 2010; Li et al., 2017). However, 
it was also found that rapamycin inhibits osteoblast proliferation and differentiation in 
MC3T3-E1 cells. It was observed that even at low concentrations (0.1-20 nM), rapamycin 
reduced osteocalcin and osterix mRNA expression in differentiating MC3T3-E1 
osteoblasts, as well as reducing their mineralisation capacity (Singha et al., 2008). 
Rapamycin however had no effect on these parameters in fully differentiated osteoblasts 
(Singha et al., 2008).  
In this study, neither azathioprine or rapamycin had any effect on the bone phenotype in 
the osteoblast MC3T3 cell line and a minimal effect on autophagy in these cells. This 
could be due to a number of reasons. In vitro systems are an isolated cell type whereas an 
in vivo model has lots of different cell types involved and a number of complimentary 
mechanisms and pathways. In addition, a cell line can often show altered morphology and 
can often differ genetically from their tissue origin. In contrast, primary cell lines are 
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isolated directly from tissues and retain the normal morphology maintain the same 
markers and functions that would be observed in an in vivo model. Therefore, the drug 
treatment may respond differently when applied to a primary cell culture as it is more like 
to mimic the results of the in vivo study.  
In conclusion, the results of this chapter have indicated that azathioprine induces 
autophagy in bone in both healthy and DSS-treated mice. However, there was only a small 
increase in autophagy marker expression in our in vitro model and only when azathioprine 
was given in combination with bafilomycin. This modest autophagy induction had no 
effect on the mRNA expression of known osteoblast makers. Further work is required to 
determine the exact role that autophagy plays in bone remodelling with azathioprine 
treatment.  
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5.1. General discussion 
Autophagy plays a vital role in several different pathways within the body including bone 
remodelling, and in various diseases such as IBD (Valenti et al., 2016; (Henderson & 
Stevens, 2012). Bone remodelling involves both bone-forming osteoblasts and bone-
resorbing osteoclasts and any imbalance in this process can result in osteoporosis. 
Osteoporosis is characterised by low bone mass and can result in higher fracture risk 
(Sambrook & Cooper, 2010). It is often seen as a secondary disease in patients with IBD, 
with the prevalence of osteoporosis being reported in a range of 12-42% (Ali et al., 2010; 
Miznerova et al., 2013). 
Because of the risk of developing osteoporosis, especially in susceptible patients, the 
mechanism of action of IBD drugs needs to be better understood to allow for more 
targeted therapy for IBD patients. Thiopurines are widely used in the treatment of IBD 
and have been proven to be highly effective, however up to a third of patients have to 
stop treatment with thiopurines due to adverse side effects (Dart & Irving, 2017; Warner 
et al., 2018). Therefore, understanding the mechanism of action of the drugs is of 
increasing importance so that thiopurine therapy can be tailored and personalised to the 
individual receiving treatment (Dart & Irving, 2017).  
In this thesis, I looked at the effect of azathioprine, a commonly prescribed immune-
suppressive IBD drug, on the skeleton in a DSS-induced colitis in vivo model. Moreover, 
to enable examination of the mechanism of azathioprine action, preliminary experiments 
were conducted on an osteoblast cell line. 
The DSS-model of IBD is most often used to look at histological changes in the colon 
associated with chronic IBD. The colitis induced in the DSS-model happens as a result of 
the deterioration of the epithelial barrier which causes an increase in cell apoptosis and a 
reduction in proliferation (Hamdani et al., 2008). DSS-induced colitis has also been 
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shown to cause reduced bone health in young male mice, both juvenile mice at 4 weeks 
old and young adults at 10 weeks. Trabecular and cortical bone compartments were found 
to be affected in younger mice whilst altered microarchitecture was observed in older 
mice (Hamdani et al., 2008; Harris et al., 2009; Dobie et al., 2018).  
Azathioprine treatment in my in vivo model detailed here resulted in trabecular bone loss, 
independent of colitis induction. Trabecular bone is less dense than cortical bone which 
makes it weaker and more flexible. Trabecular bone also has a higher level of porosity in 
comparison to cortical bone. The increase porosity allows more free surfaces which 
results in trabecular bone exhibiting more metabolic activity in comparison to cortical 
bone which causes it to be more responsive to different stimuli (Jacobs., 2000). Because 
of this trabecular bone is more susceptible to changes such as altered microarchitecture 
than cortical bone which could explain the lack of changes in cortical bone geometry 
following treatment with azathioprine seen here. Our results confirm what has been 
previously found in a study on a rat model where bone loss was also observed following 
treatment with azathioprine (Cegiela et al., 2013). Although the length of the bones was 
not reduced, the trabeculae was found to be thinner in both studies and an overall loss of 
bone mass was observed (Cegiela et al., 2013). This suggests that azathioprine alone may 
therefore not be a suitable drug of choice in IBD patients who are more at risk of 
osteoporotic bone fractures, such as the elderly. However, there are very few studies 
looking at the effect of azathioprine on bone health and further work is required to 
elucidate these effects (see section 5.2).  
In this thesis, we also assessed the effects of DSS on the mucosal integrity in our mouse 
model. Acute and chronic colitis is characterised by different changes to the colon. Acute 
inflammation is linked with epithelial degradation and an increase in neutrophils. Chronic 
inflammation however is associated with an increase in mononuclear leukocytes and 
crypt regeneration (Dobie et al., 2018). The histological analysis in this study confirms 
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that the current design used herein is sufficient to induce chronic inflammation in the in 
vivo model. In the DSS treated mice significant crypt damage was observed along with 
an increase in inflammation severity. The azathioprine treatment was seen to provide 
partial protection against DSS induced crypt damage, however there were no significant 
changes seen in any of the parameters between the vehicle and azathioprine DSS 
treatment groups. Chronic inflammation has previously been linked with autophagy, and 
it has been observed that autophagy influence the development of inflammatory cells, 
including lymphocytes, neutrophils and macrophages, all of which play crucial roles in 
the development of inflammation (Qian et al., 2017).  
Furthermore, azathioprine has previously been shown to induce autophagy in peripheral 
blood mononuclear cells and colorectal cancer cells (Hooper et al, 2019; Chaabane & 
Appell, 2016). Autophagy has previously been implicated in skeletal maintenance, 
increased autophagy has been found during osteoblast differentiation and mineralisation 
and it was observed that autophagy is highly expressed in osteocytes in response to 
starvation and hypoxia (Pierrefite-Carle et al., 2015). In this study, we found that 
azathioprine induced autophagy in the bone in the mouse model in both the healthy 
control group and the mice treated with DSS. However, this was not observed in our 
preliminary experiments looking at autophagy markers following azathioprine treatment 
in MC3T3 osteoblast cells. This could be due to the inability of azathioprine to induce 
autophagy in this osteoblast cell line or could be the concentration of azathioprine used 
in the study. There is very little research looking at the effect of azathioprine on bone and 
to our knowledge, no studies have been done to establish the effects of azathioprine on 
osteoblasts. Therefore, the drug concentration used in this study could be optimised in 
future work.  Because of this, it is currently unclear as to whether the in vivo increase in 
autophagy seen in this study occurs as a direct effect of azathioprine or acts as a survival 
mechanism in response to adverse effects caused by the azathioprine treatment. 
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Azathioprine can cause pancreatitis, hepatitis and fevers and in this thesis, it has been 
observed that treatment with azathioprine can cause a reduction in bone health. Therefore, 
it is important to determine whether autophagy is being induced in response to the cellular 
stress caused by these effects. This could be done by measuring apoptosis using 
microscopy and flow cytometry.  
In conclusion, this thesis has identified that azathioprine provides partial protection 
against bone loss in DSS-treated mice, however when administered to a healthy group it 
causes significant bone loss. It has also been shown that azathioprine induces autophagy 
in the skeleton of healthy and colitis-induced mice. Preliminary results in the MC3T3 
osteoblast cell line showed little change in osteoblast or autophagy maker expression, 
therefore highlighting the need for further work to identify the exact mechanism of action 
of azathioprine in bone.  
 
5.2. Future work 
The results presented in this study have shown that azathioprine can have detrimental 
effects to bone health in vivo and have confirmed that azathioprine can induce autophagy 
in the skeleton. However, further work is needed to identify the exact mechanism 
underpinning this. 
To further examine the levels of inflammation in the in vivo model, blood tests may be 
carried out to test for proteins such as C-reactive protein (CRP) which increases in the 
presence of inflammation. CRP is a protein produced in hepatocytes in low quantities. 
During inflammation CRP expression increases due to the influence of IL-6, IL-1b and 
TNF (Tsampalieros et al., 2011).  
To determine whether azathioprine is having a direct effect on bone via an autophagy-
dependent mechanism, Atg5 deficient mice (Kuma et al., 2017) could be utilised to assess 
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the effect of azathioprine on bone without the presence of autophagy. It has been 
previously observed in Atg7 deficient mice that the suppression of autophagy in 
osteocytes mimics skeletal aging resulting in decreased trabecular and cortical bone 
volume and an increase in cortical porosity (Onal et al., 2013). Furthermore, it was found 
that autophagy deficient osteoblasts exhibit and increase in oxidative stress and produces 
NF-kB. In vivo, it was observed that in osteoblast specific autophagy mice there was a 
decrease in trabecular mass (Nollet et al., 2014). Th would allow the role of autophagy 
induced by azathioprine treatment to be confirmed by comparing the bone damage caused 
in autophagy deficient mice  
In addition to examining azathioprine on an osteoblast cell line, primary cell lines could 
instead be utilised. Primary cell lines are isolated directly from the tissue and are able to 
preserve their original functions and characteristics. Immortalised cells, however, may 
lack the functions of normal cells that have been lost during their lifespan. Because of 
this, primary cells may therefore provide a more reliable examination of azathioprine 
effects on osteoblast function. 
Investigating the effect of azathioprine on osteoclast function would be greatly beneficial 
in furthering our understanding of the cause of bone loss. It has previously been suggested 
that azathioprine may increase the rate of resorption by osteoclasts, thus resulting in 
overall bone loss (Cegiela et al., 2013). Azathioprine was found to cause a reduction in 
bone mass and mineral substances, as well as a reduction in  calcium content which could 
indicate increased resorption (Cegiela et al., 2013). However, the Ctx levels did not 
significantly increase in our bone model which would suggest that the effects of 
azathioprine are not altering osteoclast function. By looking at osteoclast function with 
azathioprine treatment, it could be determined if azathioprine induces autophagy in 
osteoclasts as well as determining if azathioprine treatment effects osteoclast function. 
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Finally, in order to enable translation to the human condition, the effects of azathioprine 
could be tested on osteoblasts extracted and cultured from patients undergoing a total hip 
replacement. Similarly to our prilimenary studies, the effect of azathioprine on bone 
turnover could be analysed by RT-qPCR aswell as autophagy maker expression being 
monitored by western blot or immunoflueresence staining. Furthermore, apoptosis could 
be measured along with markers of oxidative stress. This would enable determination of 
how azathioprine would effect human osteoporotic bone cells. Furthermore, genetic and 
clinical data could be utilised alongside these results to examine whether patients on 
azathioprine are more susceptible to bone fractures. This would ultimately allow more 
personalised treatments for patients that may be predisposed to developing osteoporosis. 
Overall, this could potentially provide a better quality of care for patients with IBD whilst 
reducing adverse side effects. 
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Appendix Table 1: Significance of weight changes between treatment groups of mice in 
DSS-study taken daily over the 18-day treatment period. Differences between treatment 
groups were assessed by two-way analysis of variance (ANOVA) for which tests for 
multiple comparisons were conducted. Bonferroni tests were carried out to correct for 
multiple testing between groups. 
 
 
 
Groups Significance P value
Water + vehicle vs. 3% DSS + vehicle ** 0.0011
Water + vehicle vs. 3% DSS + Azathioprine *** 0.0006
Water + Azathioprine vs. 3% DSS + Azathioprine * 0.0384
Water + vehicle vs. 3% DSS + vehicle **** <0.0001
Water + vehicle vs. 3% DSS + Azathioprine **** <0.0001
3% DSS + vehicle vs. Water + Azathioprine *** 0.0001
Water + Azathioprine vs. 3% DSS + Azathioprine **** <0.0001
Water + vehicle vs. 3% DSS + vehicle **** <0.0001
Water + vehicle vs. 3% DSS + Azathioprine **** <0.0001
3% DSS + vehicle vs. Water + Azathioprine *** 0.0001
Water + Azathioprine vs. 3% DSS + Azathioprine **** <0.0001
Water + vehicle vs. 3% DSS + vehicle *** 0.0001
Water + vehicle vs. 3% DSS + Azathioprine **** <0.0001
Water + Azathioprine vs. 3% DSS + Azathioprine *** 0.0006
Water + vehicle vs. 3% DSS + vehicle ** 0.0013
Water + vehicle vs. 3% DSS + Azathioprine **** <0.0001
Water + vehicle vs. 3% DSS + vehicle * 0.0267
Water + vehicle vs. 3% DSS + Azathioprine ** 0.0051
Water + vehicle vs. 3% DSS + vehicle * 0.0195
Water + vehicle vs. 3% DSS + Azathioprine * 0.0256
Water + vehicle vs. 3% DSS + vehicle ** 0.0033
Water + vehicle vs. Water + Azathioprine * 0.0158
Water + vehicle vs. 3% DSS + Azathioprine *** 0.0008
Water + vehicle vs. 3% DSS + vehicle *** 0.001
Water + vehicle vs. Water + Azathioprine ** 0.002
Water + vehicle vs. 3% DSS + Azathioprine **** <0.0001
Water + vehicle vs. 3% DSS + vehicle ** 0.0067
Water + vehicle vs. Water + Azathioprine ** 0.0028
Water + vehicle vs. 3% DSS + Azathioprine *** 0.0001
Water + vehicle vs. 3% DSS + vehicle *** 0.0007
Water + vehicle vs. Water + Azathioprine *** 0.0001
Water + vehicle vs. 3% DSS + Azathioprine **** <0.0001
Water + vehicle vs. 3% DSS + vehicle * 0.0105
Water + vehicle vs. Water + Azathioprine ** 0.0059
Water + vehicle vs. 3% DSS + Azathioprine **** <0.0001
Water + vehicle vs. 3% DSS + vehicle ** 0.0045
Water + vehicle vs. Water + Azathioprine *** 0.0003
Water + vehicle vs. 3% DSS + Azathioprine **** <0.0001
Water + vehicle vs. 3% DSS + vehicle *** 0.0001
Water + vehicle vs. Water + Azathioprine **** <0.0001
Water + vehicle vs. 3% DSS + Azathioprine **** <0.0001
Day 17
Day 18
Day 11
Day 12
Day 13
Day 14
Day 15
Day 16
Day 10
Day 5
Day 6
Day 7
Day 8
Day 9
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Appendix 2: Immunohistochemical labelling of IgG control in tibial trabecular and 
cortical bone in sections of the tibia in 10-week old WT mice. Scale bar = 20µm. Images 
are representative of 4 different mice/group 
IgG IHC - Trabecular 
